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ABSTRACT 
Heparan sulfate (HS) glycosaminoglycans participate in critical biological processes by modulating 
the activity of a diverse set of protein binding partners. Such proteins include all known members of 
the chemokine superfamily, which are thought to guide the migration of distinct subsets of immune 
cells through their interactions with HS proteoglycans on endothelial cell surfaces. Animal-derived 
heparin polysaccharides have been shown to reduce inflammation levels through the inhibition of 
HS-chemokine interactions; however, the clinical usage of heparin as an anti-inflammatory drug is 
hampered by its anticoagulant activity and potential risk for side effects, such as heparin-induced 
thrombocytopenia (HIT). 
Here, we describe an expedient, divergent synthesis to prepare defined glycomimetics of HS that 
recapitulate the macromolecular structure and biological activity of natural HS glycosaminoglycans. 
Our synthetic approach uses a core disaccharide precursor to generate a library of four differentially 
sulfated polymers. We show that a trisulfated glycopolymer antagonizes the chemotactic activities 
of pro-inflammatory chemokine RANTES with similar potency as heparin polysaccharide, without 
potentiating the anticoagulant activities of antithrombin III. The same glycopolymer also inhibited 
the homeostatic chemokine SDF-1 with significantly more efficacy than heparin. Our work offers a 
general strategy for modulating chemokines and dissecting the pleiotropic functions of HS/heparin 
through the presentation of defined sulfation motifs within multivalent polymeric scaffolds. 
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C h a p t e r  1  
HEPARAN SULFATE AND HEPARIN POLYSACCHARIDES 
Structural Features of Heparan Sulfate Proteoglycans  
Heparan sulfate (HS) proteoglycans are cell surface and extracellular matrix macromolecules that 
comprise a core protein to which HS glycosaminoglycan (GAG) chains are covalently linked. Their 
remarkable structural diversity and ubiquitous expression allows them to regulate a wide variety of 
normal and pathophysiological activities, including development, blood coagulation, metastasis, 
angiogenesis, and inflammation.[1] HS proteoglycans can be classified into three families based on 
their core protein structure: membrane-spanning proteoglycans (syndecans, betaglycans, CD44v3), 
glycosylphosphatidylinositol (GPI)-linked proteoglycans (glypicans), and secreted extracellular 
matrix proteoglycans (perlecan, agrin, collagen XVII). Hematopoietic stem cells also carry an 
intracellular proteoglycan known as serglycin, which is important for the retention of several 
inflammatory mediators in storage granules and secretory vesicles. Some HS proteoglycans are 
hybridized with chondroitin sulfate (CS) and/or dermatan sulfate (DS) chains, resulting in even 
greater diversification of their biological activities. Notably, all major forms of HS proteoglycans 
are evolutionarily conserved from vertebrates to Drosophilia and C. elegans, thereby enabling their 
functional and genetic analyses in model organism systems.[2] 
The structural complexity of HS proteoglycans arises largely from heterogeneous sugar chains that 
decorate the core protein. HS chains are assembled by the three-step sequential action (initiation, 
polymerization, and elaboration) of glycosyltransferase and modification enzymes found in the 
Golgi (Figure 1). Nascent HS polysaccharides arise from the stepwise addition of D-glucuronic acid 
(GlcA) and N-acetylglucosamine (GlcNAc) units to the reducing end of an initiating tetrasaccharide 
linker (xylose-galactose-galactose-uronic acid), generating a backbone of 40-300 units in length.[3] 
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Further modifications are then made at distinct sites along the polysaccharide chain, which include 
N-deacetylation and N-sulfonation of GlcNAc, C5 epimerization of GlcA to L-iduronic acid (IdoA), 
and O-sulfonation at the 2-O position of IdoA or GlcA and the 6-O or 3-O positions of GlcNAc. 
Importantly, the overall organization of the anionic sulfate and carboxyl groups dictate the precise 
location of the ligand-binding sites, and their addition to the chain is regulated by cell type and the 
presence of specific growth factors in the extracellular environment.[4]  
 
 
Figure 1. Macromolecular organization and fine structure of heparan sulfate (HS) and heparin. Biosynthesis is initiated by 
the addition of xylose to serine residues on the core protein. Extl3 attaches the first N-acetyl-D-glucosamine (GlcNAc), and 
then an enzyme complex comprised of Ext1 and Ext2 adds repeating units of GlcA and GlcNAc to the nascent chain. Late-
stage processing of the chain includes deacetylation and N-sulfonation of GlcNAc by N-deacetylase-N-sulfotransferase 
(Ndst), C5 epimerization of D-glucoronic acid (GlcA) to L-iduronic acid (IdoA) by C5 epimerase (HsGlce), and a series of 
O-sulfonation modifications by uronyl 2-O-sulfotransferase (Hs2st), glucosaminyl 6-O-sulfotransferases (Hs6st1-3), and 
glucosaminyl 3-O-sulfotransferases (Hs3st1, 2, 3a, 3b, 4, 5, 6). Modifications generally occur within N-sulfated (NS) 
domains, which are interspersed by unmodified N-acetylated (NA) domains. Adapted from [3]. 
 
The anticoagulant drug heparin, purified from the secretory granules of mast cells, shares many of 
the structural features of HS; in fact, the two species are referred to interchangeably in the chemical 
literature.[5] Like HS, heparin is comprised of alternating units of glucosamine and uronic acid, and 
can undergo epimerization, N-sulfonation, and O-sulfonation at the same positions. On average, 
heparin contains 2.3 sulfate groups per disaccharide unit, while HS possesses 0.8 sulfate groups.[3] 
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Thus, heparin exhibits higher overall levels of N-sulfation and has greater conversion of GlcA to 
IdoA, which facilitates elaborations such as 6-O-sulfonation of glucosamine residues and 2-O-
sulfonation of uronic acid residues.[6] As a result, trisulfated disaccharide IdoA2S-GlcNS6S is the 
major repeating unit found within heparin polysaccharides and constitutes the majority of the N-
sulfated (NS) domains. In contrast, HS chains have large clusters of unmodified GlcNAc and GlcA 
residues that form the N-acetylated (NA) domains (Figure 1). These domains are interspersed by NS 
and mixed NS/NA clusters, both of which enable HS proteoglycans to recognize multiple types of 
protein ligands. 
 
 
 
Figure 2. Multiple activities of HS proteoglycans in cells and tissues. HS proteoglycans are involved in ligand presentation 
and sequestration, receptor activation, clustering, and signaling, receptor-mediated endocytosis, cell adhesion and motility, 
and cytoskeleton interactions. Adapted from [3] and [7]. 
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HS proteoglycans participate in multiple biological processes through modulating the activities of 
diverse protein binding partners, including cytokines, chemokines, growth factors, protease and 
protease inhibitors, and extracellular matrix factors (Figure 2).[3] For a more detailed review of the 
physiological roles of HS proteoglycans and their protein interactions, please refer to Bishop et al.[7] 
Briefly, such interactions generate a depot of regulatory factors that are essentially liberated by the 
degradation of HS chains or the removal of their sulfate modifications by either heparanase or 6-O-
endoglucosamine-sulfatase (Sulf), respectively.[8] HS proteoglycans can also serve as coreceptors in 
ligand-receptor interactions by presenting ligands in a more active configuration to their cognate 
receptors, lowering the threshold required for receptor signaling and activation, and altering the 
duration of signaling cascades.[9] Similarly, they can act as the primary receptors for the clearance of 
bound ligands, which is particularly relevant to lipoprotein metabolism in the liver and the etiology 
of hypertriglyceridemia.[10] Finally, HS proteoglycans have been shown to promote the formation of 
long-range gradients, such as morphogen gradients that are required for cell differentiation during 
development[11] and chemokine gradients that are utilized for the recruitment and homing of specific 
leukocyte populations.[12]  
 
Specificity of Heparan Sulfate and Heparin-Binding Ligands 
Glycan-binding proteins (also known as lectins) typically have a carbohydrate recognition domain 
of defined protein folds and/or sequence motifs that designates their membership in one of many 
conserved gene families.[13] However, HS-binding proteins are a noted exception to this paradigm, 
as they do not require a common fold and/or sequence motif for carbohydrate interactions. Instead, 
HS-binding proteins display positively-charged amino acids on both their external surfaces and 
shallow grooves, often within noncontiguous clusters, that make key electrostatic contacts with the 
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sulfated regions of HS chains. Hydrogen bonds, van der Waal forces, and hydrophobic effects have 
been shown to further stabilize these interactions.[14] In contrast to these common peptide sequences, 
defined sugar motifs that engage proteins have only been identified for a small subset of cases. The 
best-studied example to date is the high affinity interaction between heparin and antithrombin III 
(ATIII), a complex which is able to reduce the risk of blood clots by potentiating ATIII activity in 
the coagulation cascade. Through a series of structure-function analyses, a specific glucosaminyl 3-
O-sulfated pentasaccharide (GlcNAc6SO3-GlcA-GlcNSO3,3,6SO3-IdoA2SO3-GlcNSO3,6SO3)[15] 
has been identified as the minimal epitope required for this interaction. A methylated form of this 
pentasaccharide is now commercially distributed as the drug Arixtra (GlaxoSmithKline) as a safer 
alternative to heparin for the treatment of thrombosis.[16] 
While most ligands do not require uronyl 3-O sulfation, the study of heparin-ATIII interactions has 
instigated the search for other HS/heparin motifs that can engage specific protein binding partners. 
This pursuit has proven to be technically demanding, given the heterogeneity of the macromolecular 
organization (sulfated and non-sulfated domains, chain length) and fine structure (sulfation motifs, 
monosaccharide identity, glycosidic linkage type) of HS/heparin polysaccharides. However, using a 
combined approach of fractionation, sequencing, and mass spectrometry, the requisite fragments of 
sulfated oligosaccharides have been identified for some ligands, including fibroblast growth factor 2 
(FGF2),[17] vascular endothelial growth factor (VEGF),[18] platelet-derived growth factor (PDGF),[19] 
platelet factor 4 (PF4),[20] and L-selectin.[21] Extracellular Sulf enzymes have also been shown to 
regulate the activity of several growth factors (e.g. FGF2, FGF4, GDNF, Wnt) in vivo, suggesting a 
potential role for glucosaminyl 6-O-sulfation in these growth factor interactions.[22] Mapping the 
exact HS sequences necessary for these interactions to occur, however, still remains an area of 
active investigation. 
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Figure 3. Representation of the lowest energy models for the molecular docking of HS/heparin interactions with IL-8 and 
PF4 oligomers. Proteins are represented by ribbons, except for side chains that are directly involved in polysaccharide 
interactions; HS/heparin polysaccharides are represented by sticks. Adapted from [25]. 
 
The macromolecular arrangement of sulfated and non-sulfated domains plays a key role in ligand 
engagement, especially for the formation of higher-order oligomers. This paradigm has been closely 
examined for the chemokine superfamily, a set of small (8-10 kDa) secreted proteins that signal 
through G-protein coupled receptors (GPCRs) on cell surfaces.[23] The binding of chemokines to HS 
chains permits their local retention on the endothelium and facilitates their formation of oligomers 
that may be required for in vivo activity.[24] To date, no co-crystal structures have been reported for 
complexes of HS polysaccharides and chemokines. However, molecular docking predicts that NS 
regions are able to force the polysaccharide into a horseshoe configuration to make critical contacts 
with distal antiparallel α-helices in the chemokine dimer (Figure 3).[25] In further support of this 
model, biochemical studies have shown that the dimerization of IL-8 (interleukin-8) necessitates a 
22-24mer comprised of two NS blocks separated by an unsulfated block of ~14 monosaccharides; 
in the absence of a sufficiently long NA sequence to flank the S domains, dimerization of IL-8 is 
unable to occur.[26] This horseshoe arrangement for HS/heparin chains is also thought to facilitate 
the oligomerization of the antigenic PF4 tetramer involved in heparin-induced thrombocytopenia 
(HIT).[27] However, definitive evidence for the oligomerization of proteins as a result of HS/heparin 
spatial reorganization has yet to be uncovered.   
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Figure 4. Energy-minimized structures of HS/heparin polysaccharide chains containing the 1C4 (chair) or 2S0 (skew-boat) 
IdoA conformer. Adapted from [29]. 
 
Nonsulfated NA domains are generally believed to confer greater flexibility to the polysaccharide 
and facilitate ligand binding. In contrast, closely spaced sulfated groups in NS domains are expected 
to produce a stiffer chain due to charge repulsion. This concept has been further explored using 15N 
NMR and molecular simulations on N-acetyl (K5) heparosan, both of which strongly indicate that 
nonsulfated chains behave as disordered random coils.[28] Recent evidence also points to a special 
role for IdoA residues to provide additional conformational plurality to the polysaccharide. Within 
HS/heparin chains, IdoA typically exists in equilibrium in either the 1C4 (chair) or 2S0 (skew-boat) 
conformation (Figure 4). Protein binding interactions drive the equilibrium towards one of the two 
conformers in solution, as observed for ATIII-bound heparin oligosaccharides that predominantly 
contain 2S0.[29] Consequently, conformationally-locked derivatives of HS/heparin unable to form the 
2S0 conformer have reduced affinities for ATIII.[30] The IdoA conformer equilibrium is also affected 
by O-sulfation status of neighboring GlcA units, suggesting that the optimization of protein contacts 
for these interactions is a highly dynamic process involving the regulation of multiple heparin/HS 
biosynthesis and remodeling enzymes.[31]  
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Heparin-Based Therapeutics in Inflammatory Disease  
Unfractionated heparin and its derivatives (in particular, low molecular weight heparin and Arixtra) 
serve as some of the most important anticoagulants in the clinic today.[32] These drugs are widely 
utilized in the prevention and treatment of venous thrombosis and pulmonary embolism, as well as 
for the management of arterial thrombosis in patients with acute myocardial infarction.[33] While 
heparin has primarily been exploited for its anticoagulant properties, it has long been known to also 
possess strong anti-inflammatory activity, which is not surprising given its ability to target a large 
number of ligands such as chemokines, cytokines, growth factors, and metalloproteinases.[34] After 
heparin was first introduced as an anticoagulant in the clinic, multiple studies emerged describing a 
noticeable improvement in asthma symptoms for patients on intravenous heparin therapy.[35] More 
recently, controlled trials with heparin[36] and low molecular weight derivative enoxaparin[37] have 
shown that the inhaled form of this polysaccharide can inhibit the bronchoconstrictive response for 
exercise-induced asthma patients. Furthermore, heparin treatment is also known to promote healing 
in cases of ulcerative colitis,[38] myocardia ischemia-reperfusion injuries,[39] and burn injuries.[40]  
While there is great potential for heparin as an anti-inflammatory agent, its practical application for 
the treatment of acute and chronic inflammatory diseases is limited by its anticoagulant activity and 
high risk for complications, such as heparin-induced thrombocytopenia (HIT).[41] Even mimetics of 
heparin with reduced anticoagulant activities can be potentially dangerous, such as in the case of PI-
88 (Progen Pharmaceuticals), an anti-tumor drug that exhibited serious bleeding for some patients 
during Phase II trials.[42] Considerable efforts have been devoted to the preparation of completely 
non-anticoagulant derivatives that are still able to retain the anti-inflammatory properties of heparin. 
This is a challenging task, as one third of endogenous heparin chains contain the pentasaccharide 
sequence that activates ATIII, and active glucosaminyl 3-O-sulfate groups are difficult to remove in 
the presence of other sulfate modifications. For example, the chemical procedure used to desulfate 
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at this specific position also removes uronyl 2-O sulfates. Simultaneous loss of both modifications 
mitigates the anti-inflammatory properties of the polysaccharide, as shown in animal models of 
thioglycollate-induced peritonitis and oxazolone-induced delayed-type hypersensitivity.[43] The de 
novo synthesis of non-3-O-sulfated heparin compounds is not a reasonable alternative to pursue[44] 
given the number of stereoselective glycosylation reactions and regioselective sulfate modifications 
that would be necessitated by such preparations. Despite the inherent challenges of dissecting the 
anti-inflammatory properties of HS/heparin from its undesired anticoagulant properties, the 
production of such agents would allow for global modulation of the immune response through the 
ability to target multiple proteins in the inflammatory cascade. 
The development of HS/heparin analogs with novel and sometimes unpredictable properties offers a 
unique solution towards resolving this goal. One approach to designing HS/heparin mimetics is to 
amplify the bioactive sequences using a multivalent scaffold, such as hyperbranched dendrimers of 
defined structure and molecular weight. This strategy was utilized by Seeberger and coworkers to 
conjugate amine-functionalized heparin oligosaccharides to a carboxylic acid-containing dendrimer 
core (Figure 5).[45] The authors found that synthetic glycodendrimers not only bound to FGF-2 more 
effectively than monovalent heparin oligosaccharides, but also potentiated mitogen-activated kinase 
signaling for the ligand. The glycodendrimers were similarly effective at disrupting the migration of 
splenocyte and lymph node cells towards pro-inflammatory chemokine (CCL21) gradients, but not 
homeostatic chemokine (CXCL12 and CCL19) gradients in vitro.[46] Given the pleiotropic functions 
of HS/heparin polysaccharides, it is not surprising that these mimetics showed robust activity in 
multiple biological contexts. While the anticoagulant activity of these compounds was not studied, 
such experiments in the future would allow one to determine if synthetic glycodendrimers could be 
utilized as anti-inflammatory agents in vivo.  
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Figure 5. Glycodendrimer structures conjugated with amine-functionalized heparin oligosaccharides. Adapted from [45]. 
 
A second strategy towards obtaining non-anticoagulant, anti-inflammatory mimetics is to conduct a 
high-throughput screen on a large library of compounds using these defined criteria. For example, 
Progen Pharmaceuticals recently developed a new series of homogenously sulfated, single entity 
sugars attached to an aglycone lipophilic moiety (PG500) based on the chemical structure of the 
original PI-88 drug.[47] The new series of compounds was first screened for potential anticoagulant 
activity in human plasma, and any compound that altered the activated partial thromboplastin (PT) 
time for blood clotting was eliminated from further testing. Next, the anti-angiogenesis and anti-
metastasis activities of the remaining compounds were evaluated using in vivo tumor growth and 
proliferation assays. Several PG500 compounds exhibited strong inhibitory activity against the most 
aggressive types of tumors. Not surprisingly, the same hits targeted FGF1, FGF2, and VEGF with 
exceptional potency, suggesting that the in vivo efficacy of a drug within a tumor niche is correlated 
with its in vitro binding preferences. While compounds in the PG500 series have not been tested for 
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anti-inflammatory activity, it is reasonable to predict that several of the compounds with low anti-
coagulant activity would also be effective in in vivo animal models of inflammation and injury.  
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C h a p t e r 2
SYNTHESIS OF DIFFERENTIALLY SULFATED HS GLYCOPOLYMERS 
Aims and Justification 
Figure 6. The inflammation cascade for leukocyte extravasation. Leukocytes first make contact with endothelial cells, 
and are then activated by chemokines to achieve firm adhesion through the expression of integrins. This process allows 
leukocytes to transmigrate through the vessel wall and subendothelial basement membrane into the inflamed tissue. 
Each of these steps is mediated in part by the expression of HS proteoglycans (not shown). Adapted from [6].[6] 
The inflammatory response is a multi-stage process involving the rapid recruitment of leukocytes 
in the bloodstream to sites of inflammation, typically through post-capillary venules (Figure 6).[1] 
First, rolling leukocytes attach to the inflamed endothelium through their expression of three 
calcium-dependent (C-type) lectins: L-selectin, which is constitutively expressed by leukocytes, 
and P-selectin and E-selectin, which are expressed on endothelial surfaces upon activation by pro-
inflammatory cytokines.[2] These interactions sufficiently reduce the rolling velocity of leukocytes 
to facilitate: (1) the activation of G protein-coupled receptors (GPCRs) by endothelium-bound 
chemokines; (2) the upregulation of leukocyte integrins that enable highly stable interactions with 
the endothelium surface.[3] Once the leukocytes have been activated, they are able to traverse 
through the endothelial layer and subendothelial basement membrane. This process is facilitated 
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by the deployment of degradative enzymes, such as matrix metalloproteinases and heparanse.[4] 
Transmigration in vivo typically takes 15-45 minutes,[5] and each step is heavily regulated by the 
expression of heparan sulfate (HS) proteoglycans on the inflamed vascular endothelium and in 
the extracellular matrix. The ubiquitous expression of HS proteoglycans is necessary for the 
establishment of both the acute and chronic inflammatory response of the immune system. 
The sugar chains of HS proteoglycans are assembled from disaccharide subunits exhibiting subtle 
variations in stereochemistry, length, and patterns of sulfation. This structural diversity enables 
HS proteoglycans to modulate the activity of >400 proteins,[7] including chemokines, integrins, L- 
and P-selectin, and multiple components of the subendothelial basement membrane. HS has 
previously been identified as the dominant ligand for L-selectin during leukocyte rolling and 
adhesion activities, and the targeted deletion of endothelial HS biosynthesis (Ndst1) results in 
impaired neutrophil infiltration for multiple models of inflammation.[8] Here we will focus on a 
role for HS proteoglycans in modulating chemokine presentation and gradient formation during 
leukocyte extravasation,[9] as most members of the chemokine family possess a carboxyl terminus 
stretch of positively charged residues that recognize negatively charged HS chains with moderate 
affinity.[10] Such interactions have been characterized for both homeostatic and pro-inflammatory 
chemokines in vitro and were recently found to be relevant in vivo for the regulation of CCL21, a 
key mediator of the lymphatic trafficking of dendritic cells and T-cells.[9]  
Chemokines control the activation and migration of specific leukocyte populations toward sites of 
injury and inflammation, and the accumulation of pro-inflammatory chemokines into epithelial 
spaces contributes to the pathogenesis of allergy, arthritis, psoriasis, and other inflammatory 
disorders.[11] Although HS proteoglycans are known to establish chemoattractant gradients that 
promote leukocyte migration,[12] the precise carbohydrate structural determinants involved have 
yet to be elucidated. A major challenge to understanding the structure-activity relationships of HS 
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and developing relevant therapeutics is the chemical complexity and heterogeneity of the sugars 
found in vivo. This limitation, often referred to as the “sulfation code” for glycosaminoglycans,[13] 
has hindered the development of HS-based strategies for targeting the activity of chemokines and 
other ligands. While genetic ablation of HS biosynthesis enzymes (e.g. Ndst1, Ext1) can be used 
to map out the spatial[8] and temporal[9] regulation of HS and to identify functional roles, it lacks 
the chemical precision to indicate which sequences are involved. However, it is anticipated that 
homogeneous libraries of well-defined HS oligosaccharides may provide new insights into the 
molecular mechanisms of chemokine signaling, oligomerization, and receptor activation and their 
precise interactions with HS. 
General glycosaminoglycan libraries can been used to determine which carbohydrate classes are 
implicated in chemokine binding and activation. In a competitive binding assay for the inhibition 
of RANTES, heparin (IC50 = 25 ng/mL) was found to have the highest affinity, while chondroitin 
sulfate C (IC50 = 50 ng/mL), heparan sulfate (IC50 = 150 ng/mL), dermatan sulfate (IC50 = 800 
ng/mL), and chondroitin sulfate A (IC50 = 8 µg/mL) all interacted with the chemokine with lower 
affinity.[14] Data has also been reported for the binding of IL-8,[15] PF-4,[16] IP-10,[17] MIP-1α,[18] 
and MIP-1β[19] to heparin polysaccharides, which typically exhibit strong chemokine interactions 
due to the prevalence of their highly sulfated domains. Not surprisingly, heparin has been shown 
to have potent anti-inflammatory activity in multiple models of asthma, chronic dermatitis, and 
ulcerative colitis.[20] However, due to its well-characterized anticoagulant activity and high risk 
for bleeding, it is not recommended for use as an anti-inflammatory agent. Moreover, heparin 
polysaccharides isolated from natural sources are prone to undesirable side effects as a result of 
their structural heterogeneity and potential for external contamination.[21]  
As previously described, the development of chemically-defined HS/heparin mimetics lacking the 
glucosaminyl 3-O-sulfate anticoagulant sequence offers a promising solution to these challenges. 
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Although a few studies have partially modified natural polysaccharides[22] or undertaken the semi-
synthesis of glucan sulfate mimetics[23] towards this goal, such approaches lack the precision of 
chemical synthesis in controlling the sulfation sequence. To our knowledge, only one study[24] has 
exploited chemical synthesis to generate complex, HS-based oligosaccharides that modulate the 
activity of pro-inflammatory chemokines; however, this study did not explore the anticoagulant 
function of the macromolecular structures that they generated. Here, we describe a new class of 
simplified HS/heparin glycomimetics that have highly tunable structures, controllable lengths, 
and defined sulfation motifs. Importantly, these molecules possess the ability to inhibit the pro-
inflammatory chemokine RANTES with similar efficiency to natural heparin polysaccharides, yet 
they do not affect the activity of key factors in the coagulation cascade. The ability to control the 
fine structure within the glycopolymers is significant, as it allows for the generation of mimetics 
with distinct functions. We envision that this class of glycopolymers can serve as potential tools 
for dissecting the pleiotropic roles of HS/heparin and other glycosaminoglycans and manipulating 
their functions in vivo.  
 
Rational Design of a RANTES-Targeting Glycopolymer  
Chemokines are a superfamily of small proteins (8-10 kDa) with a highly conserved monomeric 
structure.[25] They can be grouped into four subclasses based on the positioning of their conserved 
cysteine residues: C, CX3C, CC, and CXC. While the sequence identity at the primary level can 
be as low as 20% for some chemokines, their conserved structures are mediated by a common 
four-cysteine motif that imposes the formation of two disulfide bridges.[26] Most chemokines are 
highly basic in composition (MIP-1α and MIP-1β being the only two exceptions), exhibiting an 
isoelectric point of ~9.0 that facilitates their high affinity interactions with heparin, HS, and other 
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glycosaminoglycans. While all chemokines are able to bind to heparin with varying affinities, a 
conserved sequence of basic amino acid residues, known as the BBXB motif (B represents either 
arginine and lysine, X represents any other amino acid) is found in CC chemokines.[26] This key 
motif was identified in the surface-exposed 40s loop of RANTES (44RKNR47) and has since been 
recognized as the major heparin-binding site for most chemokines through detailed mutagenesis 
studies.[14]  
 
 
Figure 7. Stereo diagrams of the heparin disaccharide-binding site in crystals of RANTES trimer. Putative hydrogen 
bonds are shown in violet. Adapted from reference [27].  
 
Based on the plethora of biochemical[14,26] and structural[27] information available for RANTES-
heparin interactions, we chose to investigate whether HS glycopolymers could be synthetically 
tailored to target the BBXB motif of RANTES. Upon examining a co-crystal structure of heparin 
disaccharide and RANTES oligomers (Figure 7),[27] we envisaged that heparin/HS disaccharide 
epitopes appended onto a multivalent polymer backbone might be sufficient to target the heparin 
binding site, provided that the binding affinity of the epitopes could be enhanced through avidity 
(Scheme 1a). We hypothesized that a trisulfated heparin-based motif would be able to interact 
efficiently with RANTES (glycopolymer 1, Scheme 1b), given that all three of its sulfates make 
contacts with basic clusters including the 44RKNR47 site. Mutations to the BBXB motif reduces 
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the binding affinity of RANTES for heparin and other glycosaminoglycans, and also abrogates its 
interactions with cognate receptors CCR1 and CCR3, but not CCR5.[26] Based on this data and the 
known receptor binding domains for RANTES,[28] we anticipate that our HS/heparin mimetic 
might also be able to disrupt the RANTES-dependent activation of CCR1 and CCR3, but have no 
such effect on CCR5. 
 
 
 
Scheme 1. (a) Synthetic glycopolymers can mimic the macromolecular architecture of heparin/HS polysaccharides. (b) 
Retrosynthesis of a series of differentially sulfated HS/heparin polymers from three building blocks: phosphate donor 6, 
acceptor 7, and norbornyl-conjugated linker 8. 
 
Previous work from our group[29] has shown that chondroitin sulfate di- and tetrasaccharides can 
be amplified on a multiavalent polymer scaffold to recapitulate the activity of natural chondroitin 
sulfate polysaccharides. These glycopolymers were found to be remarkably potent in neuronal 
growth inhibition assays, demonstrating the importance of avidity in designing synthetic mimetics 
of glycosaminoglycans. Inspired by this approach, we sought to design a series of differentially 
sulfated HS/heparin glycopolymers (1 – 4) of the same macromolecular structure. In place of the 
previously used cis-octene scaffold,[29] we chose to utilize a polynorbornene backbone to allow 
for maximal control over the chain length and polydispersity during ring-opening metathesis 
polymerization (ROMP) chemistry (Scheme 1b). We chose to reduce the unsaturated backbone at 
the last stage of the synthesis so that the polymers would be able to emulate the conformational 
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plasticity found in native HS/heparin, thereby facilitating their binding to RANTES.[30] Finally, by 
controlling the sulfation pattern prior to polymerization, we sought to increase the specificity of 
the glycopolymers for RANTES inhibition. Notably, these structures would represent the first 
example of high-molecular-weight polymers prepared from minimal HS disaccharide units. 
 
Chemical Synthesis  
While several strategies[31] have been reported for the preparation of well-defined heparin/HS 
oligosaccharides, we sought to develop a modified scheme that would allow for the synthesis of a 
heparin/HS glycopolymer library using a minimum number of protection/deprotection steps. We 
proposed a divergent scheme that could produce a library of differentially sulfated polymers 1 – 4 
from a single precursor, 5 (Scheme 1b). The orthogonal protecting group for disaccharide 5 is 
distinct from those previously published,[32] as it needs to be compatible with the requirements for 
ROMP and facilitate deprotection of the glycopolymer in the final stages of the synthesis. In this 
regard, we chose to install a tert-butyldimethylsilyl (TBS) group at the C4’-hydroxyl and benzyl 
ethers (Bn) at the non-sulfated positions C3’ and C3 in order to enhance the solubility of the 
sulfated HS/heparin monomers during ROMP. Orthogonal acetyl (Ac) and levulinoyl (Lev) ester 
groups were selected for positions that would ultimately carry the O-sulfonate groups (C2’ and 
C6, respectively); the former group would also provide anchimeric assistance in forming the 1,2-
trans glycosidic linkage in the disaccharide. As indicated in the retrosynthesis analysis (Scheme 
1b), we planned to generate core precursor 5 from three building blocks: iduronic acid (IdoA) 
phosphate donor 6, glucosamine (GlcN) acceptor 7,[33] and norbornyl linker 8.[34] 
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Scheme 2. Synthesis of disaccharide core precursor 5. Reagents and conditions: (a) AcCl, Py, DMAP, CH2Cl2, -40 °C, 
quant.; (b) (i) TiBr4, CH2Cl2, (ii) 2,4,6-collidine, MeOH, CH2Cl2, 75%; (c) NaOMe, MeOH, -10 °C, 80%; (d) TBSOTf, 
Py, 0 °C, 92%; (e) HOPO(OBu)2, CH2Cl2, 4 Å MS, quant.; (f) TMSOTf, 7, CH2Cl2, 4 Å MS, 93%; (g) (i) TBAF, 
AcOH, THF, 0 °C, (ii) Cl3CCN, DBU, CH2Cl2, 0 °C, 89%; (h) BF3OEt2, 8, CH2Cl2, 4 Å MS, 80%. 
 
In previous reports,[33] Seeberger and coworkers developed an efficient route to 1,2,4-triol 9 from 
commercially available diacetone glucose in six steps. We followed these published procedures 
without modification to prepare 9, which was then used to synthesize glycosyl phosphate donor 6 
in a highly efficient series of steps (Scheme 2). First, we treated 9 with acetyl chloride (AcCl) and 
4-dimethylaminopyridine (DMAP) at -40 °C to afford triacetylated β-isomer 10 in quantitative 
yield over three cycles of recrystallization.[35] We also tried this reaction using acetic anhydride 
(Ac2O) and at higher temperatures;[36] however, these conditions consistently led to a mixture of 
α/β-pyranose and α/β-furanose isomers that could not be separated from the desired product. 
Subsequently, anomeric bromination of 10 was accomplished using titanium bromide (TiBr4) to 
form a glycosyl halide intermediate,[35] which was directly converted into 1,2-orthoester 11 using 
2,4,6-collidine as the base in 75% yield. As anticipated, the orthoester moiety locked the pyranose 
ring into the 4C1 conformation, allowing for selective cleavage of the remaining acetal under 
Zemplén conditions (NaOMe, MeOH) to deliver 12 in 80% yield.  
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Scheme 3. Intramolecular cyclization of 12 under mild acid conditions. 
 
Table 1. Reagents and conditions for C4’ protection of 12. 
Reagents Conditions Result 
4-Methoxybenzylether (PMB):    
PMBBr (4 eq), Ag2O (4 eq), CH2Cl2, 4Å MS 24 h, rt Incomplete 
PMBBr (10 eq), Ag2O (4 eq), CH2Cl2, 4Å MS 12 h, rt Incomplete; desired (minor) 
PMBBr (10 eq), Ag2O (20 eq), DMF, 4Å MS 12 h, rt Cyclized (major); desired (minor) 
PMBBr (10 eq), Ag2O (20 eq), DMF, 4Å MS 12 h, 5 °C Cyclized (major); desired (minor) 
PMBBr (4 eq), Ag2O (4 eq), THF, 4Å MS 10 h, 5 °C Cyclized (major); desired (minor) 
PMBBr (10 eq), K2CO3 (1 eq), DMF, 4Å MS 6 h, 5 °C Cyclization byproduct (major) 
PMBBr (10 eq), KHMDS (3 eq), THF, 4Å MS 12 h, rt Incomplete; decomposition 
   
[2-(Trimethylsilyl)ethoxy]methyl Acetal (SEM):   
SEMCl (3 eq), DIPEA (4 eq), CH2Cl2 12 h, 5 °C à rt Incomplete 
SEMCl (7 eq), DIPEA (10 eq), CH2Cl2 12 h, 5 °C à rt Incomplete 
SEMCl (10 eq), TBAI (3 eq) DIPEA (neat) 14 h, 5 °C à rt Incomplete; desired (minor) 
SEMCl (15 eq), TBAI (3 eq), DIPEA (neat) 16 h, 5 °C à rt Incomplete; desired (minor) 
   
Allyl Ether:   
AllylBr (5 eq), Ag2O (3 eq), TBAI (0.5 eq), DMF 24 h, rt Incomplete; decomposition  
AllylBr (5 eq), Ag2O (3 eq), TBAI (0.5 eq), DMF 24 h, rt Desired (minor); decomposition 
   
tert-Butydimethylsilyl Ether (TBS):   
TBSCl (10 eq), imidazole (2 eq), DMAP, DMF 24 h, rt Incomplete  
 
1
2 
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Installing an orthogonal protecting group at the C4’ hydroxyl of 1,2-orthoester 12 proved to be a 
unique challenge. We found this hydroxyl to be a poor nucleophile, likely due to the presence of 
the electron-withdrawing methyl ester at C5’. Moreover, the orthoester functionality was highly 
sensitive to acidic conditions and would spontaneously undergo intramolecular cyclization in the 
presence of a weak acid, thereby limiting the reaction conditions that we could explore (Scheme 
3). Some of our unsuccessful attempts at protecting the C4’ position with 4-methoxybenzylether 
(PMB), [2-(trimethylsilyl)ethoxy]methyl acetal (SEM), allyl ether, and TBS are summarized in 
Table 2. Fortuitously, we discovered two “forcing” conditions that worked efficiently: (1) excess 
tert-butyl-dimethylsilyl trifluoromethanesulfonate (TBSOTf) in neat pyridine at 0 °C delivered 13 
in 92% yield; (2) excess SEMCl assisted by tetrabutalammonium iodide (TBAI) in neat N,N-
diisopropylethylamine (DIPEA) delivered the corresponding SEM-protected 1,2-orthoester in 
88% yield. We chose to utilize the former set of conditions for the remainder of the synthesis, as 
we later found TBS-protected 1,2-orthoester 13 to be compatible with the final deprotection steps.  
The direct reaction of 1,2-orthoester 13 with acceptor 7 gave low yields of the desired IdoA-GlcN 
disaccharide 14. Conversion of 13 to the corresponding trichloroacetimidate donor also delivered 
unproductive glycosylation reactions. We therefore chose to explore the reactivity of the IdoA 
phosphate donor, which could be accessed from 13 using dibutyl phosphate (HOPO(OBu)2)[37] in 
a single quantitative step. We were pleased to discover that phosphate donor 6 reacted quickly 
with acceptor 7 and trimethylsilyl trifluoromethanesulfonate (TMSOTf, 1.3 eq)[37] to deliver the 
α-linked disaccharide 14 in 93% yield. We attributed the efficacy of this reaction to the presence 
of the electron-donating TBS group at C4’ in stabilizing the acetoxonium ion transition state, as 
other protecting groups at this position (e.g. SEM) did not facilitate the same reaction. This 
hypothesis was further validated by calculating the gas phase Mulliken charge values at the C1’ 
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position, which we found to be 0.27180 and 0.24083 for TBS and SEM, respectively (Wei-Guang 
Liu, Goddard Lab). 
To tether the resulting disaccharide to norbornyl linker 8, we converted 14 into glycosyl imidate 
15 by removing the anomeric TBS and treating the resulting hemiacetal with trichloroacetonitrile 
and 1,8-diazabicycloundec-7-ene (DBU).[38] We then explored a variety of reaction conditions for 
the glycosidic coupling of 15 and 8. While catalytic TMSOTf (typical glycosylation conditions 
used for such donors) gave a 1:1 mixture of α/β isomers, we were pleased to find that treatment 
with BF3OEt2 (0.34 eq) gave exclusively the β-isomer (δ = 4.34 ppm, J12 = 8 Hz) in 80% yield. 
Interestingly, higher amounts of BF3OEt2 promoted the formation of an anomerically-substituted 
glycosyl fluoride that could not be readily converted into the desired product. At this stage (and 
for all compounds derived from disaccharide 5), complete protons assignments necessitated the 
use of 1H, 1H-1H COSY, 1H-1H TOCSY, and 1H-13C HSQC NMR in order to differentiate the ring 
protons from the ethylene glycol protons.  
 
 
 
Scheme 4. Synthesis of glycopolymers 1 – 4. Reagents and conditions: (a) 1,3-propanedithiol, DIPEA, MeOH, 87%; 
(b) K2CO3, MeOH, 78%; (c) H2NNH2 H2O, AcOH, Py, quant.; (d) SO3Py, NEt3, Py, 55 °C, 78 – 85%; (e) Ac2O, NEt3, 
MeOH, quant.; (f) (H2IMes)(Py)2(Cl)2Ru=CHPh, DCE, MeOH, quant.; (g) (i) TMSOK, TBAI, THF, 80 – 88%, (ii) 
Pd(OH)2/charcoal, H2 (1 atm), phosphate buffer (pH = 7.4), MeOH, 37 – 55%. 
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To explore the role of sulfate group positioning in chemokine interactions, norbornyl-conjugated 
disaccharide 5 was diversified into four differentially sulfated glycopolymers (1 – 4; Scheme 3). 
First, we reduced the azide using 1,3-propanedithiol and DIPEA,[39] as we found that the presence 
of this protecting group quickly catalyzes the decomposition of 5 (presumably through a radical 
decomposition mechanism involving the norbornene moiety). The resulting intermediate was then 
treated with either potassium carbonate (K2CO3) to deprotect both ester groups, or hydrazine 
acetate[40] to selectively cleave the Lev ester. Compounds 16 and 17 were regioselectively N-
sulfated, O-sulfated, and N-acetylated for their eventual conversion into differentially sulfated 
glycopolymers. Notably, previous syntheses of HS oligosaccharides have chosen to sulfonate the 
N- and O- positions in separate steps using distinct forms of sulfur trioxide (SO3) salts for each 
reaction.[33] Here, we found convenient conditions that would enable universal sulfonation at the 
O- and N- positions: excess sulfur trioxide pyridine (SO3Py, 30 eq), freshly distilled pyridine and 
triethylamine, and mild heating conditions (55 °C) over three days. The resulting monomers (18 – 
21) were purified by Sephadex LH-20 chromatography to remove excess sulfur trioxide salts 
prior to polymerization. 
In accordance with previous procedures for the synthesis of glycopolymer mimetics,[29] we found 
that polymerization of the sulfated HS monomers with 5 mol % of Grubbs’ fast-initiating catalyst 
[(H2IMes)(Py)2(Cl)2Ru=CHPh][41] led to rapid conversion to the desired glycopolymers (22 – 25) 
within minutes. By varying the amount of catalyst, we could predictably control the polymer 
lengths within a relatively narrow polydispersity range, affording glycopolymers with lengths 
comparable to commercial heparin (Table 2). We utilized a 10:1 ratio of dichloroethane (DCE) 
and methanol (MeOH) for ROMP, as we determined this ratio to represent the minimal amount of 
MeOH required to dissolve the sulfated monomers (higher levels of MeOH compromised the 
efficacy of the catalyst and resulted in premature termination of the polymer chain). While 
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others[29] have reported that mild heating (55 °C) is necessary for the polymerization reaction to 
achieve complete conversion, we did not find this requirement to be necessary if the DCE and 
MeOH solvents were thoroughly degassed by multiple freeze-pump-thaw cycles and extended 
purge by argon, respectively. We also commenced the stirring of the reaction only after the 
catalyst was added to ensure that the solvents remained thoroughly degassed; this small alteration 
in our methodology led to considerable improvements in experimental consistency. 
 
Table 2. Properties of glycopolymers 1 – 4. 
   
Monomer 
mol% 
Catalyst 
Mna 
(g/mol) 
 
PDIa 
n 
(DP b) 
1 22 5 27,870 1.22 35 
2 23 5 36,490 1.02 48 
3 24 5 53,580 1.16 90 
4 25 5 32,880 1.03 46 
 
aNumber average molecular weight (Mn) and polydispersity index (PDI) were determined 
by size exclusion chromatography multi-angle light scattering (SEC-MALS). bDegree of 
polymerization (DP). Despite equal mol% of catalyst, the DP was notably higher for 
unsulfated monomer 24. This was likely due to increased solubility of the unsulfated 
polymer (3) in the polymerization co-solvent (10:1 dichloroethane/methanol) compared to 
the sulfated polymers (1, 2, and 4). 
 
In designing the remainder of our synthetic scheme, we reasoned that removing the methyl ester, 
benzyl ether, and TBS prior to ROMP might compromise the efficacy of the polymerization 
reaction. However, any late-stage deprotection steps performed on the glycopolymer needed to go 
to completion to ensure homogeneity of the final compounds. Thus, we decided to first optimize 
our deprotection conditions using 18 to prepare a monovalent trisulfated disaccharide with the 
norbornyl linker at the reducing end (26, see methods section for structure); identical conditions 
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were then applied to glycopolymers 22 – 25. For example, while standard conditions for methyl 
ester saponification (30% H2O2, 1M LiOH, 4N NaOH) were not found to be compatible with our 
model substrates, we were pleased to find that powerful nucleophile potassium trimethylsilanolate 
(TMSOK) not only saponified the methyl ester, but also removed the C4’ TBS group, likely due 
to its close proximity to the resulting C5’ carboxylate anion. The mechanism of this reaction 
warrants further investigation, but serves as an elegant example for how the in situ generation of a 
nucleophilic silanolate can be used to streamline the synthesis of HS oligosaccharides.   
Finally, we found that catalytic hydrogenation using Pd(OH)2/charcoal in a mixture of phosphate 
buffer (pH = 7.4) and MeOH[39] delivered final targets 26 and glycopolymers 1 – 4. The reaction 
mixture was filtered through a polyethersulfone (PES) membrane to remove excess palladium 
particles and purified using a Sephadex G-25 column. We then characterized the final polymers 
by 1H NMR spectroscopy and size exclusion chromatography multi-angle light scattering (SEC-
MALS) to determine both chemical homogeneity and molecular weight. Moreover, comparison 
of the 1H-1H COSY NMR spectrum of trisulfated monomer 26 to that of glycopolymer 1 
confirmed that all sulfate groups remained intact during the post-polymerization deprotection 
steps, given that the two compounds exhibited identical chemical shifts for cross-peaks in the ring 
proton region. These additional characterization steps allowed us to be confident in our 
assignments of the chemical structures for all four glycopolymers.   
 
Experimental Methods and Spectral Assignments  
Unless stated otherwise, reactions were performed in flame-dried glassware under an argon 
atmosphere using freshly dried solvents. Solvents were dried via passage through an activated 
alumina column under argon. All other commercially obtained reagents were used as received 
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unless otherwise noted. Thin-layer chromatography (TLC) was performed using E. Merck silica 
gel 60 F254 pre-coated plates (0.25 mm). Visualization of the chromatogram was accomplished 
by UV, cerium ammonium molybdate, or ninhydrin staining, as necessary. ICN silica gel (particle 
size 0.032 – 0.063 mm) was used for flash chromatography. Gel filtration chromatography was 
also used in order to achieve purification of the final products.    
1H and 13C NMR experiments were recorded on Varian Mercury 300 (at 300 MHz), Varian Inova 
500 (at 500 MHz), or Varian Inova 600 (600 MHz) spectrometers and are reported in parts per 
million (δ) relative to CDCl3 (7.26 ppm) or CD3OD (4.80 ppm). Data for 1H are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet), coupling constant in Hz, and integration. 13C NMR spectra were obtained on Varian 
Inova 500 (at 125 MHz) or Varian Inova 600 (at 150 MHz) spectrometers and are reported in 
terms of chemical shift (77.2 ppm for CDCl3; 49.0 for CD3OD). When necessary, proton and 
carbon assignments were made by means of 1H-1H gCOSY, 1H-1H TOCSY, and 1H-13C 
gHSQCAD. Stereochemical assignments are supported by 1H-1H ROESY spectra. Mass spectra 
were obtained using a Perkin Elmer/Sciex API 365 triple quadrupole/electrospray tandem mass 
spectrometer or a Waters LCT Premier XE high resolution mass spectrometer. 
 
 
Methyl 3-O-benzyl-L-idopyranosyluronate (9). Compound 9 was prepared in six steps from the 
commercially available diacetone glucose (Sigma Aldrich) using previously reported 
procedures.[33] The analytical data were in agreement with the reported spectra. 
O
OHOH
OBn
MeO2C
OH
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Methyl 1,2,4-tri-O-acetyl-3-O-benzyl-β-L-idopyranosyluronate (10). Compound 9 (0.30 g, 1.0 
mmol) was added to CH2Cl2 (5.5 mL) at 0 °C, and the solution was cooled to -40 °C. 4-
Dimethylaminopyridine (120 mg, 0.10 mmol) was added, followed by pyridine (700 µL, 10 
mmol). Acetyl chloride (470 µL, 6.0 mmol) was then added dropwise to the reaction mixture, 
which was stirred for 10 h at -40 °C. The reaction was quenched with aqueous NaHCO3 (50 mL), 
extracted with CH2Cl2 (2.0 x 50 mL), and subsequently washed with H2O, 1M H2SO4, and then 
H2O (50 mL for each wash). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. Purification by silica gel flash chromatography (3:1 
hexanes:EtOAc) afforded compound 10 (0.40 g) in quantitative yield. The analytical data were in 
agreement with previously reported spectra.[35] ESI-TOF HRMS: m/z calcd for C20H23O10 [M+H]-
H2 423.1286; found: 423.1286.   
 
 
Methyl 4-O-acetyl-3-O-benzyl-β-L-idopyranuronate 1,2-(methyl-orthoacetate) (11). TiBr4 
(8.1 g, 22 mmol) was added to a solution of compound 10 (6.9 g, 16 mmol) in CH2Cl2 (360 mL), 
and the reaction was stirred for 16 h at ambient temperature with exclusion of light. The reaction 
was quenched with ice-cold H2O (2.0 x 500 mL), filtered through Celite, and concentrated under 
reduced pressure. The resulting brown oil was immediately used in the next reaction without 
O
OAcOAc
OBn
MeO2C OAc
O
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OBn
MeO2C
O
O
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further purification. The crude bromide intermediate (16 mmol) was dissolved in CH2Cl2 (220 
mL). 2,4,6-Collidine (11 mL, 80 mmol) and methanol (8.0 mL) were added to this solution, and 
the reaction was stirred for 14 h at room temperature (rt). The reaction mixture was then diluted 
with CH2Cl2 (500 mL), washed with aqueous NaHCO3 and H2O (200 mL each), dried over 
MgSO4, and concentrated under reduced pressure. Purification by silica gel flash chromatography 
(6:1 hexanes:EtOAc + 1% Et3N) afforded 11 (7.6 g, 75% over 2 steps) as a light yellow oil. 1H 
NMR (500 MHz; CDCl3): δ 7.44 – 7.30 (m, 5H, OCH2Ph), 5.57 (d, J = 2.7 Hz, 1H, H-1), 5.20 
(dt, J = 2.7, 1.3 Hz, 1H, H-4), 4.82 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.69 (d, J = 11.7 Hz, 1H, 
OCH2Ph), 4.56 (d, J = 1.4 Hz, 1H, H-5), 4.15 (dd, J = 2.7, 1.9 Hz, 1H, H-3), 4.09 (ddd, J = 2.9, 
1.9, 1.2 Hz, 1H, H-2), 3.79 (s, 3H, CO2CH3), 3.26 (s, 3H, OCH3), 2.05 (s, 3H, OCOCH3), 1.74 (s, 
3H, CH3); 13C NMR (125 MHz; CDCl3): δ 170.1, 168.1, 136.8, 128.6, 128.4, 128.0, 96.6, 77.3, 
76.1, 72.9, 71.3, 69.6, 68.9, 52.6, 49.1, 25.0, 20.1; ESI-TOF HRMS: m/z calcd for C19H23O9 
[M+H]-H2 395.1342; found: 395.1354.   
 
 
Methyl 3-O-benzyl-β-L-idopyranuronate 1,2-(methyl-orthoacetate) (12). Compound 11 (7.2 
g, 18 mmol) was dissolved in methanol (90 mL) and cooled to -10 °C. A 0.5 M solution NaOMe 
(1.8 mL, 0.91 mmol) was added, and the reaction mixture was stirred at -10 °C for 2 h and at 5 °C 
overnight. The solution was diluted with CH2Cl2 (200 mL) at 5 °C, quenched with aqueous 
NaHCO3 and H2O (500 mL each), and then extracted with (3.0 x 250 mL). The organic fractions 
were dried over MgSO4 and concentrated under reduced pressure. Purification by silica gel flash 
chromatography (4:1 à 1:1 hexanes:EtOAc + 1% Et3N) yielded 12 (9.5 g, 80%) as a clear oil. 1H 
O
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NMR (500 MHz; CDCl3): δ 7.36 – 7.34 (m, 5H, OCH2Ph), 5.51 (d, J = 2.4 Hz, 1H, H-1), 4.72 (d, 
J = 11.7 Hz, 1H, OCH2Ph), 4.62 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.52 (s, 1H, H-4), 4.15 – 4.08 (m, 
3H, H-2, H-5), 3.81 (s, 3H, CO2CH3), 3.30 (s, 3H, OCH3), 2.78 (d, J = 11.4 Hz, 1H, H-3), 1.76 (s, 
3H, CH3); 13C NMR (125 MHz; CDCl3): δ 168.3, 136.8, 128.7, 128.4, 127.9, 96.8, 75.8, 73.0, 
72.9, 71.8, 67.0, 52.5, 50.3, 24.4; ESI-TOF HRMS: m/z calcd for C17H21O8 [M+H]-H2 353.1236; 
found: 353.1226.   
 
 
Methyl 3-O-benzyl-4-O-tert-butyldimethylsilyl-β-L-idopyranuronate 1,2-(methyl-orthoace-
tate) (13). Compound 12 (230 mg, 0.64 mmol) was dissolved in pyridine (7.8 mL) and the 
solution was cooled to -10 °C. TBSOTf (1.5 mL, 0.65 mmol) was added, and the reaction was 
stirred overnight at 0 °C. The reaction was diluted with CH2Cl2 (100 mL), quenched with aqueous 
NaHCO3 (100 mL), and extracted with EtOAc (3.0 x 50 mL). The combined organic fractions 
were dried over MgSO4 and concentrated under reduced pressure. Purification by silica gel flash 
chromatography (7:1 hexanes:EtOAc + 1% Et3N) yielded compound 32 (380 mg, 92%) as a clear 
oil. 1H NMR (500 MHz; CDCl3): δ 7.47 (m, 5H, OCH2Ph), 5.62 (d, J = 2.5 Hz, 1H, H-1), 4.80 (d, 
J = 12 Hz, 1H, OCH2Ph), 4.75 (d, J = 12 Hz, 1H, OCH2Ph), 4.51 (s, 1H, H-4), 4.21 (s, 1H, H-5), 
4.20 (d, J = 1 Hz, 1H, H-4), 3.98 (s, 1H, H-3), 3.89 (s, 3H, CO2CH3), 3.40 (s, 3H, OCH3), 1.84 (s, 
3H, CH3), 0.94 (s, 9H, SiC(CH3)3), 0.08 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3); 13C NMR (125 MHz; 
CDCl3): δ 169.6, 137.0, 128.9, 128.6, 128.2, 124.6, 97.1, 76.3. 74.6, 72.8, 72.5, 67.9, 52.4, 49.5, 
29.9, 25.7, 25.6, -4.4, -5.2; TOF HRMS ES m/z calcd for C23H36O8SiNa [M+Na]+: 491.2077; 
found: 491.2070.  
O
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Methyl (dibutylphosphate-2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyra-
nosid)uronate (6). Compound 13 (140 mg, 0.29 mmol) was dissolved in CH2Cl2 (7.3 mL) at rt. 
Freshly activated 4Å molecular sieves (290 mg) were added, and the solution was stirred for 15 
min. Dibutylphosphate (0.54 mL, 2.9 mmol) was added slowly, and the reaction mixture was 
stirred overnight. After confirming that the reaction was complete by TLC, the reaction was 
quenched with triethylamine (2.0 mL) and concentrated under reduced pressure. Silica gel flash 
chromatography (5:1 à 3:1 hexanes:EtOAc + 1% Et3N) afforded the desired product (170 mg) in 
quantitative yield. 1H NMR (500 MHz; CDCl3): δ 7.36 – 7.35 (m, 5H, OCH2Ph), 5.82 (d, J = 7.2 
Hz, 1H, H-1), 4.97 (m, 1H, H-2), 4.86 (d, J = 2.7 Hz, 1H, H-5), 4.78 (d, J = 12 Hz, 1H, OCH2Ph), 
4.62 (d, J = 12 Hz, 1H, OCH2Ph), 4.09 – 3.99 (m, 5H, H-4, P(OCH2CH2CH3)2), 3.77 (s, 3H, 
CO2CH3), 3.62 (m, 1H, H-3), 2.04 (s, 3H, COCH3), 1.64 – 1.60 (m, 4H, P(OCH2CH2CH2CH3)2), 
1.40 – 1.25 (m, 4H, P(OCH2CH2CH2CH3)2), 0.96 – 0.88 (m, 6H, P(OCH2CH2CH2CH3)2), 0.81 (s, 
9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), 0.17 (s, 3H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 169.8, 
169.2, 146.6, 137.3, 128.4, 128.0, 95.4, 73.8, 72.0, 68.0, 67.8, 67.0, 66.9, 52.1, 32.1, 25.4, 20.9, 
18.6, 17.8, 13.5, -4.7, -5.7; ESI-TOF HRMS m/z calcd for C30H52O11PSi [M+H]+: 647.3017; 
found: 647.3001. 
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2-O-Azido-3-O-benzyl-6-O-levulinoyl-1-O-tert-butyldimethylsilyl-2-deoxy-β-D-glucopyrano-
side (7). Compound 7 was prepared from readily available D-glucosamine (Sigma Aldrich) using 
previously published procedures, and the analytical data were in agreement with previously 
reported spectra.[33] 
 
 
2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethanol (8). Compound 8 was prepared 
using a previously published procedure, and the analytical data were in agreement with reported 
spectra.[34] 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-
tert-butyldimethylsilyl (2-azido-3-O-benzyl-6-O-levulinoyl-2-deoxy-β-D-glucopyranoside) 
(14). Compound 6 (92 mg, 0.14 mmol) and 7 (77 mg, 0.17 mmol) were co-evaporated with 
toluene (3.0 x 1.0 mL) and placed under vacuum overnight. The mixture was dissolved in CH2Cl2 
(4.2 mL), and freshly activated 4Å molecular sieves (0.21 g) were added. After stirring at rt for 
15 min, the temperature was lowered to -10 °C and the mixture stirred for an additional 15 min. 
TMSOTf (31 µL, 0.18 mmol) was added dropwise to the reaction mixture. The reaction was 
stirred at -30 °C for 30 min, quenched with Et3N (1.0 mL), filtered through a silica pad, and 
HO O
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concentrated under reduced pressure. Silica gel flash chromatography (5:1 à 4:1 
hexanes:EtOAc) afforded the desired product (120 mg) in 93% yield. 1H NMR (600 MHz; 
CDCl3): δ 7.37 – 7.24 (m, 10H, OCH2Ph), 5.20 (d, J = 4.2 Hz, 1H, H-1 of IdoA), 4.85 (t, J = 4.1 
Hz, 1H, H-2 of IdoA), 4.82 (d, J = 10.6 Hz, 1H, OCH2Ph), 4.74 (d, J = 11.8 Hz, 1H, OCH2Ph), 
4.71 (d, J = 10.8 Hz, 1H, OCH2Ph), 4.69 (d, J = 3.9 Hz, 1H, H-5 of IdoA), 4.64 (d, J = 11.8 Hz, 
1H, OCH2Ph), 4.54 (dd, J = 11.8, 2.1 Hz, 1H, H-1 of GlcN), 4.51 – 4.45 (m, 1H, H-6), 4.20 – 
4.03 (m, 1H, H-6), 3.99 (t, J = 4.3 Hz, 1H, H-4 of IdoA), 3.91 – 3.77 (m, 1H, H-4 of GlcN), 3.61 
(t, J = 4.3 Hz, 1H, H-3 of IdoA), 3.54 (s, 3H, CO2CH3), 3.48 (ddd, J = 9.8, 5.9, 2.2 Hz, 1H, H-5 
of GlcN), 3.37 – 3.24 (m, 2H, H-2 and H-3 of GlcN), 2.89 – 2.66 (m, 2H, COCH2CH2COCH3), 
2.61 (t, J = 6.7 Hz, 2H, COCH2CH2COCH3), 2.19 (s, 3H, COCH2CH2COCH3), 2.00 (s, 3H, 
COCH3), 0.92 (s, 9H, SiC(CH3)3), 0.81 (s, 9H, SiC(CH3)3), 0.13 (d, J = 4.6 Hz, 6H, SiCH3), -0.06 
(s, 3H, SiCH3), -0.12 (s, 3H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 206.5, 172.2, 170.2, 169.9, 
138.2, 137.7, 128.5, 128.1, 128.1, 127.9, 127.4, 97.6, 97.1, 80.6, 76.8, 76.5, 75.4, 74.8, 73.4, 72.7, 
71.5, 69.9, 68.9, 68.5, 62.6, 51.7, 38.0, 29.9, 28.0, 25.6, 25.5, 20.9, 18.0, 17.8, -4.3, -4.7, -5.2, -
5.5; ESI-TOF HRMS m/z calcd for C46H69N3O14Si2 [M+Na]+: 966.4216; found: 966.4211. 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-
2-azido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-yl-methoxy)ethoxy)ethyl)-6-O-
levulinoyl-2-deoxy-α-D-glucopyranoside (5). Compound 15 (37 mg, 60 µmol) and 8 (33 mg, 70 
µmol) were co-evaporated with toluene (3.0 x 1.0 mL) and placed under vacuum overnight. The 
O
OAcOTBS
OBn
MeO2C
O
O
OLev
BnO
N3
O O
H
2
38	  
mixture was dissolved in CH2Cl2 (1.7 mL) and freshly activated 4Å molecular sieves (80 mg) 
were added. After stirring at rt for 15 min, the temperature was lowered to -30 °C and the mixture 
stirred for an additional 15 min. TMSOTf (14 µL, 70 µmol) was added to dropwise to the 
reaction mixture. The reaction was stirred at -10 °C for 10 min, slowly raised to rt over 15 min, 
quenched with Et3N (0.50 mL), filtered through a silica pad, and concentrated under reduced 
pressure. Silica gel flash chromatography (10:1 à 4:1 à 3:1 hexanes:EtOAc) afforded the 
desired product (35 mg) in 67% yield. 1H NMR (500 MHz; CDCl3): δ 7.38 – 7.25 (m, 10H, 
OCH2Ph), 6.07 (ddd, J = 25.6, 5.7, 3.0 Hz, 2H, CH=CH of Nb), 5.19 (d, J = 4.2 Hz, 1H, H-1 of 
IdoA), 4.89 – 4.79 (m, 2H, H-2 of IdoA, OCH2Ph), 4.72 – 4.68 (m, 3H, H-5 of IdoA, OCH2Ph), 
4.64 (d, J = 11.9 Hz, 1H, OCH2Ph), 4.52 (dd, J = 12.1, 2.2 Hz, 1H, H-6 of GlcN), 4.34 (d, J = 7.9 
Hz, 1H, H-1 of GlcN), 4.12 (dd, J = 12.1, 2.2 Hz, 1H, H-6 of GlcN), 4.02 – 3.93 (m, 2H, H-4 of 
IdoA, OCH2 of PEG linker), 3.87 (dd, J = 9.8, 8.9 Hz, 1H, H-4 of GlcN), 3.82 – 3.55 (m, 5H, H-3 
of IdoA, OCH2 of PEG linker), 3.54 (s, 3H, CO2CH3), 3.53 – 3.29 (m, 5H, H-5 of GlcN, H-2 of 
GlcN, H-3 of GlcN, OCH2 of PEG linker), 2.88 – 2.67 (m, 4H, CH-CH=CH of Nb, 
COCH2CH2COCH3), 2.67 – 2.56 (m, 2H, COCH2CH2COCH3), 2.19 (s, 3H, COCH2CH2COCH3), 
2.00 (s, 3H, OCOCH3), 1.75 – 1.66 (m, 1H, CH of Nb), 1.39 – 1.15 (m, 4H, CH2 of Nb), 0.81 (s, 
9H, SiC(CH3)), -0.06 (s, 3H, SiCH3), -0.11 (s, 3H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 136.6, 
128.5, 128.2, 127.8, 102.2, 80.9, 76.8, 76.1, 75.0, 73.2, 72.9, 71.6, 70.7, 70.4, 66.0, 45.0, 43.6, 
38.8, 38.0, 29.8, 28.1, 25.5; ESI-TOF HRMS m/z calcd for C52H73N3O16Si [M+Na]+: 1046.4658; 
found: 1046.4670 
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Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-
2-azido-3-O-benzyl-6-O-levulinoyl-2-deoxy-β-D-glucopyranosyl trichloroacetimidate (15). 
Compound 14 (840 mg, 0.89 mmol) was dissolved in THF (27 mL) and the solution was cooled 
to 0 °C. 1M TBAF (1.2 mL, 1.2 mmol) and AcOH (60 µL, 1.1 mmol) were added 
simultaneously, and the reaction was stirred for 30 min at 0 °C. The reaction was quenched with 
aqueous NaHCO3 (10 mL), extracted with CH2Cl2 (2.0 x 10 mL), and subsequently washed with 
H2O, 1M H2SO4, and then H2O (10 mL for each wash). After concentrating under reduced 
pressure, the crude mixture (0.89 mmol) was dissolved in CH2Cl2 (27 mL) and cooled to 0 °C. To 
the reaction mixture, trichloroacetonitrile (1.3 mL, 13 mmol) and DBU (26 µL, 0.18 mmol) were 
added. The reaction was stirred at 0 °C for 12 h, quenched with Et3N (1.0 mL), and concentrated 
under reduced pressure. Silica gel flash chromatography (5:1 à 4:1 à 3:1 hexanes:EtOAc + 1% 
Et3N) afforded the desired product (770 mg) in 89% yield over two steps. 1H NMR (600 MHz; 
CDCl3): δ 8.72 (s, 1H, OCNHCCl3), 7.47 – 7.28 (m, 10H, OCH2Ph), 6.37 (d, J = 3.6 Hz, 1H, H-1 
of IdoA), 5.24 (d, J = 4.7 Hz, 1H, H-1 of GlcN), 4.96 (d, J = 10.5 Hz, 1H, OCH2Ph), 4.90 (t, J = 
4.4 Hz, 1H, H-2 of GlcN), 4.75 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.71 (d, J = 10.5 Hz, 1H, 
OCH2Ph), 4.66 (d, J = 11.8 Hz, 1H, OCH2Ph), 4.63 (d, J = 4.2 Hz, 1H, H-5 of GlcN), 4.52 (dd, J 
= 12.3, 1.8 Hz, 1H, H-6 of GlcN), 4.13 (dd, J = 12.3, 4.3 Hz, 1H, H-6 of GlcN), 4.08 – 3.98 (m, 
3H, H-4 and H-5 of IdoA, H-4 of GlcN), 3.91 (dd, J = 10.2, 8.5 Hz, 1H, H-3 of IdoA), 3.69 (dd, J 
= 10.2, 3.6 Hz, 1H, H-2 of IdoA), 3.66 – 3.61 (m, 1H, H-3 of GlcN), 3.57 (s, 3H, CO2CH3), 2.89 
– 2.69 (m, 2H, COCH2CH2COCH3), 2.67 – 2.54 (m, 2H, COCH2CH2COCH3), 2.18 (s, 3H, 
COCH2CH2COCH3), 2.01 (s, 3H, COCH3), 0.82 (d, J = 2.5 Hz, 9H, SiC(CH3)3), -0.05 (s, 3H, 
SiCH3), -0.09 (s, 3H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 206.5, 172.1, 170.2, 170.0, 160.7, 
137.7, 137.6, 128.7, 128.2, 128.1, 128.0, 127.9, 127.6, 97.7, 94.4, 78.2, 77.2, 76.7, 75.1, 75.0, 
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73.0, 72.0, 71.9, 70.2, 69.0, 62.8, 61.9, 51.7, 38.0, 29.9, 28.0, 25.5, 20.1, 17.8, 4.7, 5.4; ESI-TOF 
HRMS m/z calcd for C42H55N3O15SiCl3 [M+Na]+: 997.2366; found: 997.2415. 
 
 
 
Methyl 3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-2-amino-3-
O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-deoxy-α-D-glu 
-copyranoside (16). Compound 5 (17 mg, 20 µmol) was dissolved in anhydrous MeOH (0.80 
mL), and 1,3-propanedithiol (0.14 mL, 60 µmol) and DIPEA (0.12 mL, 60 µmol) were added 
dropwise.  Upon confirmation of partial disappearance of 5 by TLC, flame-dried K2CO3 (2.4 mg, 
20 µmol) was added and the reaction mixture was stirred for 24 h at rt. The reaction was 
quenched with Dowex 5W-X8 (H+ form), filtered through a pad of Celite, and concentrated under 
reduced pressure. Silica gel flash chromatography (1:1 hexanes:EtOAc) afforded the desired 
product (14 mg) in 93% yield. 1H NMR (500 MHz; CDCl3): δ 7.48 – 7.20 (m, 10H, OCH2Ph), 
6.17 – 5.88 (m, 2H, CH=CH of Nb), 5.25 (d, J = 4.5 Hz, 1H, H-1 of IdoA), 4.96 (d, J = 11.4 Hz, 
1H, OCH2Ph), 4.83 (d, J = 11.4 Hz, 1H, OCH2Ph), 4.68 – 4.51 (m, 3H, OCH2Ph, H-5 of IdoA), 
4.32 (d, J = 8.0 Hz, 1H, H-1 of GlcN), 4.09 – 3.76 (m, 5H, H-6 of IdoA, H-4 of IdoA, H-2 of 
IdoA, OCH2 of PEG linker), 3.76 – 3.53 (m, 10H, H-2 of IdoA, H-6 of IdoA, OCH2 of PEG 
linker, CO2CH3), 3.47 – 3.32 (m, 4H, H-4 of GlcN, OCH2 of PEG linker, H-5 of GlcN, H-3 of 
GlcN), 2.84 – 2.68 (m, 3H, H-2 of GlcN, CH-CH=CH of Nb), 1.69 – 1.63 (m, 1H, CH of Nb), 
1.40 – 1.03 (m, 4H, CH2 of Nb), 0.82 (s, 9H, SiC(CH3)), -0.03 (d, J = 7.3 Hz, 7H, SiCH3); 13C 
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NMR (125 MHz; CD3OD): δ 171.7, 140.1, 139.7, 137.7, 137.5, 129.2, 128.8, 128.4, 104.5, 102.3, 
84.1, 79.5, 77.7, 77.0, 75.2, 74.4, 72.8, 71.5, 71.4, 61.8, 57.8, 52.4, 45.8, 44.9, 42.8, 40.1, 30.6, 
26.1, 18.7, -4.5, -5.1; ESI-TOF HRMS: m/z calcd for C45H66NO13Si [M-H]- 856.4303; found: 
856.4326. 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-
2-acetylamido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)eth-
yl)-2-deoxy-α-D-glucopyranoside (17). Compound 5 (190 mg, 0.18 mmol) was dissolved in 
anhydrous MeOH (11 mL). 1,3-propanedithiol (1.1 mL, 5.4 mmol) and DIPEA (1.1 mL, 6.3 
mmol) were added dropwise, and the reaction mixture was stirred for 24 h at rt. The reaction was 
quenched with Dowex 5W-X8 (H+ form), filtered through a pad of Celite, and concentrated under 
reduced pressure. Silica gel flash chromatography (30:2:1 à 20:2:1 EtOAc:MeOH:H2O) afforded 
the desired product (150 mg), and the resulting intermediate was dissolved in pyridine (2.8 mL). 
To this mixture, a solution of hydrazine monohydrate (1.2 mmol) and AcOH (9.9 mmol) in 
pyridine (17 mL) was added at rt. The reaction mixture was diluted with CH2Cl2 (10 mL), washed 
with cold water (15 mL), saturated NaHCO3 (15 mL), water (15 mL), and saturated brine (15 
mL). The combined organic fractions were dried over MgSO4 and concentrated under reduced 
pressure. Silica gel flash chromatography (20:2:1 EtOAc:MeOH:H2O) afforded the desired 
product (140 mg) in 87% yield over two steps. 1H NMR (500 MHz; CDCl3): δ 7.46 – 7.27 (m, 
10H, OCH2Ph), 6.14 – 5.98 (m, 2H, CH=CH of Nb), 5.31 (d, J = 4.4 Hz, 1H, H-1 of IdoA), 4.99 
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(d, J = 11.2 Hz, 1H, OCH2Ph), 4.88 (q, J = 3.6 Hz, 1H, H-2 of IdoA), 4.80 – 4.68 (m, 2H, 
OCH2Ph, H-5 of IdoA), 4.67 – 4.55 (m, 2H, OCH2Ph), 4.36 (dt, J = 8.0, 4.1 Hz, 1H, H-1 of 
GlcN), 4.05 – 3.85 (m, 4H, H-4 of IdoA, H-6 of GlcN, H-5 of GlcN, OCH2 of PEG linker), 3.85 – 
3.34 (m, 15H, OCH2 of PEG linker, H-6 of GlcN, H-3 of IdoA, CO2CH3, H-3 of GlcN, H-4 of 
GlcN), 2.89 (dd, J = 10.0, 7.8 Hz, 1H, H-2 of GlcN), 2.81 – 2.67 (m, 2H, CH-CH=CH of Nb), 
2.01 (s, 3H, OCOCH3), 1.42 – 1.14 (m, 5H, CH and CH2 of Nb), 0.82 (s, 9H, SiC(CH3)), -0.08 (d, 
J = 7.3 Hz, 6H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 170.2, 138.7, 137.8, 136.7, 128.5, 128.1, 
127.9, 127.6, 97.8, 76.8, 76.2, 75.7, 75.5, 74.2, 72.7, 72.0, 70.7, 70.4, 69.3, 69.0, 61.7, 56.6, 51.9, 
45.1, 43.8, 41.7, 38.9, 38.6, 29.9, 25.7, 21.1, 17.9, -4.5, -5.4; ESI-TOF HRMS: m/z calcd for 
C47H70NO14Si [M-H]- 900.4565; found: 900.4568. 
 
 
Methyl 3-O-benzyl-2-O-sulfonato-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à  
4)-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-deoxy-2-
sulfonatamido-6-O-sulfonato-α-D-glucopyranoside (18). Compound 16 (9.2 mg, 10 µmol) was 
dissolved in freshly distilled pyridine (1.0 mL) and to this SO3•Py (50 mg, 0.32 mmol) and Et3N 
(0.20 mL) were added. The reaction mixture was stirred at rt for 24 h, refluxed at 50 °C for 24 h, 
quenched with MeOH (1.0 mL), and concentrated to afford a golden syrup. Purification by 
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH) followed by silica gel flash chromatography 
(15:2:1 à 10:2:1 à 8:2:1 EtOAc:MeOH:H2O) gave the desired product (8.7 mg) in 78% yield. 
1H NMR (500 MHz; CD3OD): δ 7.51 – 7.50 (m, 2H, OCH2Ph), 7.43 – 7.41 (m, 2H, OCH2Ph), 
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7.37 – 7.34 (m, 2H, OCH2Ph), 7.30 – 7.26 (m, 3H, OCH2Ph), 7.23 – 7.22 (m, 1H, OCH2Ph), 6.11 
– 6.04 (m, 2H, CH=CH of Nb), 5.30 (s, H-1 of IdoA), 4.98 (d, J = 12.5 Hz, 1H, OCH2Ph), 4.87 
(d, J = 11.5 Hz, 1H, OCH2Ph), 4.78 (d, J = 6 Hz, 1H, H-1 of GlcN), 4.67 (d, J = 11.5 Hz, 1H, 
OCH2Ph), 4.59 (d, J = 12.5 Hz, 1H, OCH2Ph), 4.43 (s, 1H, H-2 of IdoA), 4.37 – 4.28 (m, 2H, H-
6, H-6 of GlcN), 4.13 – 4.12 (m, 1H, H-4 of GlcN), 4.05 – 4.03 (m, 1H, H-5 of GlcN), 3.96 – 
3.93 (m, 1H, H-4 of IdoA), 3.81 – 3.78 (m, 2H, H-3 of IdoA, OCH2 of PEG linker), 3.73 – 3.71 
(m, 2H, OCH2 of PEG linker), 3.69 – 3.56 (m, 5H, OCH2 of PEG linker), 3.54 – 3.51 (m, 1H, H-2 
of GlcN), 3.45 – 3.35 (m, 2H, OCH2 of PEG linker), 3.15 (s, 3H, CO2CH3), 2.77 (s, 1H, CH-
CH=CH of Nb), 2.72 (s, 1H, CH-CH=CH of Nb), 2.11 (s, 3H, OCOCH3), 1.98 (s, 3H, OCOCH3), 
1.72 – 1.68 (m, 1H, CH of Nb), 1.38 – 1.21 (m, 3H, CH2 of Nb), 1.15 – 1.12 (m, 1H, CH2 of Nb), 
0.76 (s, 9H, SiC(CH3)), -0.17 (s, 3H, SiCH3), -0.24 (s, 3H, SiCH3); 13C NMR (125 MHz; 
CD3OD): δ 172.8, 141.1, 140.4, 138.7, 131.6, 131.0, 130.6, 130.4, 130.3, 130.2, 130.0, 129.4, 
104.3, 100.1, 80.9, 78.0, 77.0, 72.7, 72.4, 71.0, 70.7, 56.2, 53.5, 46.9, 46.0, 43.8, 41.1, 31.7, 27.4, 
19.9, -3.0, -4.4; ESI-TOF HRMS: m/z calcd for C45H66NO22S3Si [M-H]- 1016.2597; found: 
1016.2583. 
 
 
Methyl 2-O-sulfonato-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à  
4)-2-acetylamido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy) 
ethyl)-2-deoxy-6-O-sulfonato-α-D-glucopyranoside (19). To a solution of compound 16 (130 
mg, 0.15 mmol) in anhydrous MeOH (8.4 mL) at ambient temperature were added Ac2O (0.30 
mL, 3.0 mmol) and Et3N (0.50 mL). Additional amounts of Ac2O (0.30 mL, 3.0 mmol) were 
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added every hour until complete conversion to the desire product was observed by TLC (at least 4 
h). The reaction mixture was directly loaded onto a Sephadex LH-20 gel filtration column and 
eluted with 1:1 CH2Cl2:MeOH. The N-acetylated intermediate was dissolved in freshly distilled 
pyridine (8.1 mL), and SO3•Py (450 mg, 3.3 mmol) and Et3N (1.6 mL) were added. The reaction 
mixture was stirred at rt for 24 h, refluxed at 50 °C for 24 h, quenched with MeOH (5.0 mL), and 
concentrated to afford a golden syrup. Purification by Sephadex LH-20 gel filtration (1:1 
CH2Cl2:MeOH) followed by silica gel flash chromatography (10:2:1 EtOAc:MeOH:H2O) gave 
the desired product (130 mg) in 85% yield over two steps. 1H NMR (500 MHz; CD3OD): δ 7.53 – 
7.10 (m, 10H, OCH2Ph), 6.12 – 5.95 (m, 2H, CH=CH of Nb), 5.35 (s, 1H, H-1 of IdoA), 4.84 (m, 
2H, H-5 of IdoA, OCH2Ph), 4.73 (d, J = 11.2 Hz, 1H, OCH2Ph), 4.60 (d, J = 11.6 Hz, 1H, 
OCH2Ph), 4.55 (d, J = 8.3 Hz, 1H, H-1 of GlcN), 4.52 (dd, J = 2.1, 1.1 Hz, 1H, H-2 of IdoA), 
4.47 (d, J = 11.2 Hz, 1H, OCH2Ph), 4.41 (dd, J = 11.3, 2.2 Hz, 1H, OCH2 of PEG linker), 4.29 
(dd, J = 11.2, 5.0 Hz, 1H, OCH2 of PEG linker), 4.00 – 3.87 (m, 4H, H-4 of IdoA, H-2 of GlcN, 
H-3 of GlcN, H-6 of GlcN), 3.86 (t, J = 1.8 Hz, 1H, H-3 of IdoA), 3.79 – 3.48 (m, 11H, H-6 of 
GlcN, OCH2 of PEG linker, H-4 of GlcN, H-5 of GlcN), 3.46 – 3.36 (m, 1H, OCH2 of PEG 
linker), 3.33 (s, 3H, CO2CH3), 2.74 (d, J = 31.6 Hz, 2H, CH-CH=CH of Nb), 1.85 (d, J = 1.2 Hz, 
3H, NHCOCH3), 1.67 (d, J = 4.5 Hz, 1H, CH of Nb), 1.39 – 1.04 (m, 4H, CH2 of Nb), 0.78 (d, J 
= 1.2 Hz, 9H, SiC(CH3)), -0.11 (dd, J = 47.6, 1.1 Hz, 6H, SiCH3); 13C NMR (125 MHz; CD3OD): 
δ 173.3, 172.1, 139.7, 139.2, 137.7, 137.5, 129.9, 129.5, 129.1, 128.6, 102.6, 99.2, 82.3, 77.1, 
76.2, 75.7, 75.3, 74.1, 72.8, 71.5, 71.4, 70.1, 69.7, 67.8, 56.5, 52.4, 45.9, 44.9, 42.8, 40.0, 30.7, 
26.2, 23.0, 18.9, -4.2, -5.4; ESI-TOF HRMS: m/z calcd for C47H67NO20NaSiS2 [M+Na]+ 
1080.3365; found: 1080.3392. 
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Methyl 3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-2-acetyl-
amido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-de-
oxy-α-D-glucopyranoside (20). To a solution of compound 16 (130 mg, 0.15 mmol) in 
anhydrous MeOH (8.4 mL) at ambient temperature were added Ac2O (0.30 mL, 3.0 mmol) and 
Et3N (0.50 mL). Additional amounts of Ac2O (0.30 mL, 3.0 mmol) were added every hour until 
complete conversion to the desired product was observed by TLC (at least 4 h). Purification by 
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH) followed by silica gel flash chromatography 
(20:2:1 EtOAc:MeOH:H2O) gave the desired product (140 mg) in quantitative yield. 1H NMR 
(600 MHz; CDCl3): δ 7.36 – 7.09 (m, 10H, OCH2Ph), 6.12 – 5.87 (m, 2H, CH=CH of Nb), 5.11 
(s, 1H, H-1 of IdoA), 4.76 – 4.72 (m, 1H, H-1 of GlcN), 4.70 (t, J = 2.7 Hz, 1H, H-4 of IdoA), 
4.68 – 4.56 (m, 2H, OCH2Ph), 4.51 – 4.43 (m, 2H, OCH2Ph), 4.00 – 3.92 (m, 1H, H-3 of IdoA), 
3.91 – 3.80 (m, 2H, OCH2 of PEG linker, H-6 of GlcN), 3.80 – 3.17 (m, 19H, H-6 of GlcN, H-2 
of GlcN, H-3 of GlcN, H-4 of GlcN, H-5 of GlcN, H-2 of IdoA, H-5 of IdoA, OCH2 of PEG 
linker, CO2CH3), 2.75 – 2.46 (m, 2H, CH-CH=CH of Nb), 1.67 (d, J = 4.2 Hz, 3H, NHCOCH3), 
1.64 – 1.53 (m, 1H, CH of Nb), 1.30 – 1.13 (m, 4H, CH2 of Nb), 0.71 (s, 9H, SiC(CH3)), -0.15 (d, 
J = 9.3 Hz, 6H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 170.4, 169.7, 138.6, 137.5, 136.8, 136.6, 
128.8, 128.4, 128.2, 127.4, 107.3, 101.6, 100.9, 78.7, 77.0, 76.4, 75.7, 75.5, 72.6, 72.5, 71.0, 70.7, 
70.4, 69.8, 69.1, 68.8, 67.2, 62.7, 52.1, 45.2, 43.8, 41.7, 38.8, 30.0, 29.9, 25.6, 23.3, 17.9, -4.7, -
5.4; ESI-TOF HRMS: m/z calcd for C47H69NaNO14Si [M+Na]+ 922.4380; found: 922.4385. 
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Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl-α-L-idopyranosyluronate-(1à4)-
3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-deoxy-2-
sulfonatamido-6-O-sulfonato-α-D-glucopyranoside (21). To a solution of compound 17 (22 
mg, 0.020 mmol) in freshly distilled pyridine (2.3 mL) were added SO3•Py (110 mg, 0.60 mmol) 
and Et3N (0.5 mL). The reaction mixture was stirred at rt for 24 h and refluxed at 50 °C for 24 h, 
quenched with MeOH (1.0 mL), and concentrated to afford a golden syrup. Purification by 
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH) followed by silica gel flash chromatography 
(15:2:1 à 10:2:1 EtOAc:MeOH:H2O) gave the desired product (26 mg) in 78% yield. 1H NMR 
(600 MHz; CD3OD): δ 7.79 – 7.03 (m, 10H, OCH2Ph), 6.25 – 5.94 (m, 2H, CH=CH of Nb), 
5.31 (d, J = 4.4 Hz, 1H, H-1 of IdoA), 5.05 – 4.76 (m, 4H, H-2 of IdoA, H-5 of IdoA, OCH2Ph), 
4.75 – 4.64 (m, 1H, OCH2Ph), 4.65 – 4.47 (m, 2H, OCH2Ph, H-1 of GlcN), 4.38 (m, 1H, H-6 of 
GlcN), 4.20 (m, 1H, H-6 of GlcN), 4.07 – 3.85 (m, 4H, H-2 of IdoA, H-2 of GlcN, H-2 of GlcN, 
OCH2 of PEG linker), 3.86 – 3.71 (m, 1H, OCH2 of PEG linker), 3.71 – 3.45 (m, H, 11H, H-3 of 
IdoA, H-3 of GlcN, H-5 of GlcN, OCH2 of PEG linker), 3.40 (s, 3H, CO2CH3), 2.81 – 2.74 (m, 
2H, CH-CH=CH of Nb), 2.07 (s, 3H, OCOCH3), 1.52 – 1.10 (m, 5H, CH and CH2 of Nb), 0.83 (s, 
9H, SiC(CH3)), -0.09 (s, 3H, SiCH3), -0.13 (s, 3H, SiCH3); 13C NMR (125 MHz; CDCl3): δ 173.3, 
172.0, 171.8, 139.8, 139.1, 137.7, 137.5, 102.8, 99.2, 82.1, 79.8, 77.1, 76.6, 76.2, 75.9, 75.3, 75.2, 
73.2, 71.5, 71.4, 71.3, 71.0, 70.1, 69.8, 69.4, 67.3, 56.3, 52.4, 45.9, 44.9, 42.8, 40.0, 37.4, 36.0, 
30.7, 23.0, 21.2, 18.7, -4.3, -5.4; ESI-TOF HRMS: m/z calcd for C47H67NO20NaSiS2 [M+Na]+ 
1080.3365; found: 1080.3392. 
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Protected HS glycopolymers (22 – 25). Monomers 18 – 21 were converted into polymers 22 – 
25, which contain the following functional groups: R1 = SO3-, R2 = SO3-, R3 = SO3- (1); R1 = SO3-, 
R2 = SO3-, R3 = Ac- (2); R1 = H, R2 = H, R3 = Ac (3); R1 = H, R2 = SO3-, R3 = SO3- (4). In a typical 
polymerization, a small vial was charged with monomer (18 – 21; 6.0 mg, 5.0 µmol) and a small 
stir bar under the flow of argon. To this was added degassed dichloroethane (DCE)/MeOH (10:1, 
0.025 M) and bis-pyridine Grubbs catalyst ((H2IMes)(Py)2(Cl)2Ru=CHPh)4 in DCE (5 mg/mL 
stock solution, 24 µL, 0.11 µmol) by syringe at rt. The reaction mixture was stirred at rt for 1 h, 
quenched with ethyl vinyl ether (0.10 mL), and diluted with diethyl ether (1.0 mL) and hexanes 
(0.50 mL) to obtain a white precipitate. The mixture was centrifuged to remove the organic layer, 
and the resulting white solid (83 – 98% conversion) was dried in vacuo. 1H NMR confirmed 
disappearance of the norbornene olefinic peaks at 6.04 – 6.11 ppm. The protected polymers were 
characterized by size exclusion chromatography multi-angle light scattering (SEC-MALS) using 
a system equipped with an MZ-Gel SDplus organic column (10E5Å, MZ Analysentechnik), a 
light scattering detector (miniDAWN, Wyatt Technology), and a refractive index detector 
(TREOS, Wyatt Technology), and 0.2 M LiBr in DMF as the mobile phase. 1H NMR (500 MHz; 
D2O): δ 7.49 – 7.15 (m, 10H), 5.42 (br, 1H), 5.18 (br, 1H), 4.75 (br, 1H), 4.65 – 4.51 (m, 2H), 
4.38 (br, 1H), 4.05 – 3.84 (m, 4H), 3.86 (br, 1H), 3.79 – 3.50 (m, 13H), 3.46 (br, 1H), 3.31 (br, 
3H) 3.30 – 3.25 (m, 2H), 2.49 (br, 2H), 1.94 (br, 3H), 1.79 – 1.07 (m, 5H), 0.77 (br, 9H), -0.07 
(br, 3H), -0.17 (br, 3H). 
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2-O-Sulfonato-α-L-idopyranosyluronate-(1à4)-1-O-(2-(2-((2S)bicyclo[2.2.1]hept-5-en-2-
ylmethoxy)ethoxy)ethyl)-2-deoxy-2-sulfonatamido-6-O-sulfonato-α-D-glucopyranoside (26). 
Compound 18 (14 mg, 0.013 mmol) was dissolved in THF (1.3 mL), and TMSOK (33 mg, 0.26 
mmol) was added to the reaction mixture. The reaction was stirred for 24 h at rt and quenched 
with MeOH (1.0 mL). The crude reaction mixture was loaded directly onto a Sephadex G-25 gel 
filtration column and eluted with 100% H2O, and fractions were combined, lyophilized, and 
subjected to hydrogenation. The intermediate was dissolved in a 3:2 mixture of 80 mM phosphate 
buffered saline (2.4 mL, pH = 7.0) and MeOH (0.80 mL). To this, Pd(OH)2/charcoal (80 mg, 8x 
by weight of starting material) was added, and the reaction was carried out under 1 atm H2 gas for 
3 d. The reaction mixture was filtered using a vacuum filtration system (0.45 µm PES membrane, 
VWR) and desalted on a Sephadex G-25 column in 100% H2O to obtain the desired product 60% 
yield after lyophilization. 1H NMR (500 MHz, D2O) δ 5.24 (s, 1H, H-1 of IdoA), 4.83 (d, J = 2.7 
Hz, 1H, H-5 of IdoA), 4.73 (d, J = 8.2 Hz, 1H, H-1 of GlcN), 4.44 (m, 1H, H-6 of GlcN), 4.34 
(m, 2H, H-6 of GlcN, H-2 of IdoA), 4.10 (m, 2H, H-3 of IdoA, H-4 of IdoA), 4.01 – 3.71 (m, 
11H, OCH2 of PEG linker, H-3 of GlcN, H-4 of GlcN, H-5 of GlcN), 3.44 – 3.31 (m, 2H, OCH2 
of PEG linker), 3.16 (m, 1H, H-2 of GlcN), 2.28 – 2.20 (m, 2H, bridgehead CH2 of Nb), 1.82 (s, 
2H, CH2 of Nb), 1.59 (s, 2H, CH2 of Nb), 1.48 – 1.36 (m, 2H, CH of Nb), 1.27 – 1.19 (m, 2H, 
CH2 of Nb), 1.08 (s, 1H, CH of Nb); ESI-TOF HRMS: m/z calcd for C24H37Na3NO22S3 [M+3Na-
H]2+ 856.0662; found: 856.0624. 
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Deprotected glycopolymers (1 – 4). Polymers 22 – 25 were deprotected to obtain final polymers 
1 – 4, which contain the following functional groups: R1 = SO3-, R2 = SO3-, R3 = SO3- (1); R1 = 
SO3-, R2 = SO3-, R3 = Ac- (2); R1 = H, R2 = H, R3 = Ac (3); R1 = H, R2 = SO3-, R3 = SO3- (4). In a 
typical reaction, polymer (11 mg, 10 µmol per unit) was dissolved in THF (1.0 mL), and TBAI 
(7.0 mg, 20 µmol) and TMSOK (25 mg, 0.20 mmol) were added. The reaction was stirred for 24 
h at rt and quenched with MeOH (1.0 mL). The crude reaction mixture was loaded directly onto a 
Sephadex G-25 gel filtration column and eluted with 100% H2O. The polymer-containing 
fractions were combined, lyophilized, and subjected to hydrogenation. In a typical hydrogenation 
reaction, the polymer from the previous reaction was dissolved in a 3:2 mixture of 80 mM 
phosphate buffered saline (0.9 mL, pH = 7.0) and MeOH (0.60 mL). To this, Pd(OH)2/charcoal 
(84 mg, 8x weight of polymer) was added, and the reaction was carried out under 1 atm H2 gas 
for 3 d. Samples were filtered using a vacuum filtration system (0.45 µm PES membrane, VWR) 
and desalted on a Sephadex G-25 column in 100% H2O to obtain the desired polymers in 35 – 
55% yield after lyophilization. 1H NMR showed disappearance of the benzyl and methyl ester 
peaks at 7.79 – 7.03 ppm and 3.40 ppm, respectively. Deprotected polymers were characterized 
by SEC-MALS using a system equipped with an OHpak water column (SB-804 HQ, Shodex), a 
light scattering detector (miniDAWN, Wyatt Technology), and a refractive index detector 
(TREOS, Wyatt Technology), and 3 mM NaN3 and 6 mM NaNO3 in H2O as the mobile phase. 1H 
NMR (500 MHz; D2O): δ 5.03 (br, 1H), 4.44 (br, 1H), 4.25 – 4.20 (m, 1H), 4.18 – 4.11 (m, 2H), 
3.92 (br, 1H), 3.84 (br, 2H), 3.75 – 3.40 (m, 12H), 3.34 (br, 1H), 3.19 (br, 1H), 1.91 (br, 3H), 1.72 
(br, 1H), 1.48 – 0.88 (m, 6H). 
n
Ph
O
OR1OH
OH
-O2C
O
O
OR2
HO
NHR3
O O 2
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67	  
REFERENCES 
[1] W. A. Muller, Trends in immunology 2003, 24, 327-334. 
[2] J. B. Lowe, Current opinion in cell biology 2003, 15, 531-538. 
[3] A. Rot, U. H. von Andrian, Annual review of immunology 2004, 22, 891-928. 
[4] C. R. Parish, E. J. Hindmarsh, M. R. Bartlett, M. A. Staykova, W. B. Cowden, D. O. 
Willenborg, Immunology and cell biology 1998, 76, 104-113. 
[5] R. Yadav, K. Y. Larbi, R. E. Young, S. Nourshargh, Thrombosis and haemostasis 2003, 
90, 598-606. 
[6] L. Raffaghello, V. Pistoia, Journal of leukocyte biology 2009, 86, 1271-1273. 
[7] A. Ori, M. C. Wilkinson, D. G. Fernig, Frontiers in bioscience : a journal and virtual 
library 2008, 13, 4309-4338. 
[8] L. Wang, M. Fuster, P. Sriramarao, J. D. Esko, Nature immunology 2005, 6, 902-910. 
[9] X. Bao, E. A. Moseman, H. Saito, B. Petryniak, A. Thiriot, S. Hatakeyama, Y. Ito, H. 
Kawashima, Y. Yamaguchi, J. B. Lowe, U. H. von Andrian, M. Fukuda, Immunity 2010, 
33, 817-829. 
[10] A. E. Proudfoot, Biochemical Society transactions 2006, 34, 422-426. 
[11] C. Gerard, B. J. Rollins, Nature immunology 2001, 2, 108-115. 
68	  
[12] A. E. Proudfoot, T. M. Handel, Z. Johnson, E. K. Lau, P. LiWang, I. Clark-Lewis, F. 
Borlat, T. N. Wells, M. H. Kosco-Vilbois, Proceedings of the National Academy of 
Sciences of the United States of America 2003, 100, 1885-1890. 
[13] C. I. Gama, S. E. Tully, N. Sotogaku, P. M. Clark, M. Rawat, N. Vaidehi, W. A. 
Goddard, 3rd, A. Nishi, L. C. Hsieh-Wilson, Nature chemical biology 2006, 2, 467-473. 
[14] L. Martin, C. Blanpain, P. Garnier, V. Wittamer, M. Parmentier, C. Vita, Biochemistry 
2001, 40, 6303-6318. 
[15] L. M. Webb, M. U. Ehrengruber, I. Clark-Lewis, M. Baggiolini, A. Rot, Proceedings of 
the National Academy of Sciences of the United States of America 1993, 90, 7158-7162. 
[16] K. H. Mayo, E. Ilyina, V. Roongta, M. Dundas, J. Joseph, C. K. Lai, T. Maione, T. J. 
Daly, The Biochemical journal 1995, 312 ( Pt 2), 357-365. 
[17] A. D. Luster, S. M. Greenberg, P. Leder, The Journal of experimental medicine 1995, 
182, 219-231. 
[18] W. Koopmann, M. S. Krangel, The Journal of biological chemistry 1997, 272, 10103-
10109. 
[19] D. Gilat, R. Hershkoviz, Y. A. Mekori, I. Vlodavsky, O. Lider, Journal of Immunology 
1994, 153, 4899-4906. 
[20] E. Young, Thrombosis research 2008, 122, 743-752. 
[21] M. Petitou, L. P. Herault, A. Bernat, P. A. Driguez, P. Duchaussoy, J. C. Lormeau, J. M. 
Herbert, Nature 1999, 398, 417-422. 
69	  
[22] L. C. Wang, J. R. Brown, A. Varki, J. D. Esko, Journal of Clinical Investigation 2002, 
110, 127-136. 
[23] S. Alban, R. J. Ludwig, G. Bendas, M. P. Schon, G. J. Oostingh, H. H. Radeke, J. 
Fritzsche, J. Pfeilschifter, R. Kaufmann, W. H. Boehncke, The Journal of investigative 
dermatology 2009, 129, 1192-1202. 
[24] J. L. de Paz, E. A. Moseman, C. Noti, L. Polito, U. H. von Andrian, P. H. Seeberger, ACS 
chemical biology 2007, 2, 735-744. 
[25] T. N. Wells, A. E. Proudfoot, Inflammation research : official journal of the European 
Histamine Research Society ... [et al.] 1999, 48, 353-362. 
[26] A. E. Proudfoot, S. Fritchley, F. Borlat, J. P. Shaw, F. Vilbois, C. Zwahlen, A. Trkola, D. 
Marchant, P. R. Clapham, T. N. Wells, The Journal of biological chemistry 2001, 276, 
10620-10626. 
[27] J. P. Shaw, Z. Johnson, F. Borlat, C. Zwahlen, A. Kungl, K. Roulin, A. Harrenga, T. N. 
Wells, A. E. Proudfoot, Structure 2004, 12, 2081-2093. 
[28] D. R. Pakianathan, E. G. Kuta, D. R. Artis, N. J. Skelton, C. A. Hebert, Biochemistry 
1997, 36, 9642-9648. 
[29] M. Rawat, C. I. Gama, J. B. Matson, L. C. Hsieh-Wilson, Journal of the American 
Chemical Society 2008, 130, 2959-2961. 
[30] A. Canales, J. Angulo, R. Ojeda, M. Bruix, R. Fayos, R. Lozano, G. Gimenez-Gallego, 
M. Martin-Lomas, P. M. Nieto, J. Jimenez-Barbero, Journal of the American Chemical 
Society 2005, 127, 5778-5779. 
70	  
[31] M. Weiwer, F. Huang, R. J. Linhardt, Abstr Pap Am Chem S 2007, 234. 
[32] A. Prabhu, A. Venot, G. J. Boons, Org Lett 2003, 5, 4975-4978. 
[33] H. A. Orgueira, A. Bartolozzi, P. Schell, R. E. Litjens, E. R. Palmacci, P. H. Seeberger, 
Chemistry 2003, 9, 140-169. 
[34] S. G. Lee, J. M. Brown, C. J. Rogers, J. B. Matson, C. Krishnamurthy, M. Rawat, L. C. 
Hsieh-Wilson, Chemical science 2010, 1, 322-325. 
[35] O. Gavard, Y. Hersant, J. Alais, V. Duverger, A. Dilhas, A. Bascou, D. Bonnaffe, Eur J 
Org Chem 2003, 3603-3620. 
[36] A. Dilhas, D. Bonnaffe, Carbohydrate research 2003, 338, 681-686. 
[37] A. Ravida, X. Liu, L. Kovacs, P. H. Seeberger, Org Lett 2006, 8, 1815-1818. 
[38] R. R. Schmidt, W. Kinzy, Advances in carbohydrate chemistry and biochemistry 1994, 
50, 21-123. 
[39] Y. P. Hu, S. Y. Lin, C. Y. Huang, M. M. Zulueta, J. Y. Liu, W. Chang, S. C. Hung, 
Nature chemistry 2011, 3, 557-563. 
[40] R. H. Fan, J. Achkar, J. M. Hernandez-Torres, A. Wei, Organic letters 2005, 7, 5095-
5098. 
[41] M. Scholl, S. Ding, C. W. Lee, R. H. Grubbs, Organic letters 1999, 1, 953-956.	  
70 
C h a p t e r 3
EVALUATION OF ANTI-CHEMOKINE ACTIVITY 
Binding Affinity of the Glycopolymer for RANTES 
With our library of differentially sulfated glycopolymers in hand, we sought to characterize their 
specificities for RANTES (CCL5), a small basic chemokine that induces leukocyte migration by 
binding to specific members of the G-protein coupled receptor (GPCR) family, namely CCR1, 
CCR3, and CCR5.[1] Specifically, RANTES is able to induce the migration of T cells, monocytes, 
natural killer cells, dendritic cells, eosinophils, basophils, and several other types of leukocytes.[2] 
RANTES is typically produced by CD8+ T cells and is a hallmark feature of >100 inflammatory 
conditions, such as allogeneic transplant rejection, atherosclerosis, arthritis, atopic dermatitis, 
asthma, delayed-type hypersensitivity reactions, and endometriosis.[3] RANTES is also known to 
be involved in the pathogenesis of several neurological disorders, such as Alzheimer’s disease.[4] 
In the aforementioned disorders, RANTES is thought to act as a pro-inflammatory chemokine 
that promotes the infiltration of leukocytes to sites of inflammation.[5] More recently, RANTES 
was also found to be a potent suppressor of replication in non-syncitum-inducing (NSI) HIV-1 
strains, leading to the identification of CCR5 as a major co-receptor for NSI HIV-1 viral entry.[6] 
The precise mechanism for RANTES-induced suppression of HIV-1 replication is currently not 
known, but may involve the dimerization of RANTES and internalization of its receptor CCR5.[7] 
In addition to its cognate receptors, RANTES associates with cell surface proteoglycans such as 
syndecan-1 and syndecan-4,[8] and its chemotactic activities can be directly inhibited by soluble 
glycosaminoglycans.[9] Furthermore, deletion of the glycosaminoglycan-binding site on RANTES 
(44RKNR47) abrogates the chemokine’s ability to form higher-order oligomers and generates a 
dominant-negative inhibitor of cell migration induced by endogenous RANTES.[10] It is well 
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established that RANTES preferentially recognizes heparin (or the trisulfated motif found in HS) 
over other glycosaminoglycan classes.[11] However, the effects of HS sulfation on binding to 
RANTES have not yet been examined using homogeneously sulfated molecules. Our synthetic 
glycopolymer library represents four distinct sulfation sequences that could potentially interact 
with RANTES with varying potencies and differentially affect its cellular activities in vitro. Here, 
we sought to compare the relative ability of each glycopolymer (1 – 4) in antagonizing RANTES 
binding to heparin polysaccharides using a competitive enzyme-linked immunosorbent assay 
(ELISA).  
 
 
 
Figure 8. Binding of RANTES to heparin, as determined by ELISA. Heparin-binding 96-well plates were coated with 
heparin (25 µg/mL; 20-kDa). Human RANTES (1 – 1024 nM; ) was serially diluted and then incubated in the 
heparin-coated plates. For ELISA analysis, RANTES was first incubated with a mouse anti-RANTES primary antibody 
and then with a goat anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP). Levels of plate-bound 
RANTES were measured by detecting HRP activity at 450 nm. Data were fitted to a sigmoidal curve to determine the 
half-maximal effective concentration (EC50) for RANTES binding to heparin. Experiments were conducted in 
quadruplicate, and the standard error is depicted.  
 
We chose to use a competitive ELISA format based on its physiological relevance (representing 
the ability of our synthetic polymers to disrupt endogenous RANTES activities) and amenability 
to high-throughput screens. First, we evaluated the half maximal effective concentration (EC50) of 
human recombinant RANTES binding to heparin-coated (25 µg/mL) 96-well plates. We prepared 
a serial dilution of RANTES (0.50 – 1024 nM) and incubated the heparin-coated plates with each 
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solution, followed by the corresponding primary and secondary antibodies. Levels of plate-bound 
chemokine were measured by detection of horseradish peroxidase (HRP), which was conjugated 
to our choice of secondary antibody. By fitting the relative values for RANTES binding to a Hill 
equation using KaleidaGraph software, we determined the EC50 to be 12.2 nM (Figure 8).  
 
 
 
Figure 9. Comparison of the ability of glycopolymers 1 – 4 to compete with heparin for binding to RANTES. P < 0.05 
for IC50 values of glycopolymers 2 and 4 compared to 1; P < 0.05 for IC50 value of 2 compared to glycopolymer 4. IC50 
values corrected for ligand valence are reported in Table 3. 
 
We used this concentration of RANTES to conduct all competitive ELISA experiments with the 
synthetic glycopolymers. We followed the same experimental format, except that RANTES was 
first preincubated with either heparin or glycopolymer, allowing us to determine the individual 
ability of each compound to inhibit RANTES binding to the heparin-bound plates. The half 
maximal inhibitory concentrations (IC50) were calculated by fitting the relative binding values to 
the Michaelis-Menten equation (Kaleidagraph software). We found that trisulfated glycopolymer 
1 bound very strongly to RANTES (IC50 = 9.3 ± 1.1 mg/mL (334 ± 39 nM)), albeit with reduced 
affinity in comparison to natural heparin polysaccharides of similar lengths (IC50 = 0.90 ± 0.03 
mg/mL (45.0 ± 1.5 nM); Figure 9). However, glycopolymer 1 was a more efficient competitor for 
RANTES at its concentration of maximum inhibition: whereas heparin exhibited a maximum 
inhibition of 58.4%, glycopolymer 1 inhibited RANTES binding by up to 90.8% under the same 
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assay conditions. Maximum inhibition values were also determined from the Michaelis-Menten 
equation.[12] As expected, trisulfated disaccharide 26 (the monovalent version of glyocopolymer 
1) failed to compete with heparin for RANTES binding in the competitive ELISA assay (Figure 
9). Thus, our results provide the first demonstration that an HS disaccharide epitope is indeed 
sufficient for chemokine binding when presented in a multivalent framework and underscore the 
importance of avidity in the recognition of glycosaminoglycan structures. 
Next, we tested whether site-defined modifications to the glycopolymer sulfation pattern would 
alter its affinity for RANTES. Removal of the N-sulfate group of GlcN (glycopolymer 2) or the 2-
O-sulfate group of IdoA (glycopolymer 4) decreased the binding to RANTES (IC50 = 31.1 ± 6.2 
mg/mL (852 ± 170 nM) and 58.0 ± 5.7 mg/mL (1760 ± 170 nM), respectively), and negative 
control glycopolymer 3 showed no appreciable activity (Figure 9). Our observation that removal 
of 2-O-sulfation has a greater effect than removal of N-sulfation implies that precise positioning 
of the sulfate groups (in addition to overall electrostatic charge) is important for determining the 
affinity of the glycopolymers for RANTES. However, this result does not determine from an 
absolute standpoint that a trisulfated motif is required for RANTES, and also does not rule out 
that other HS/heparin sequences can interact with RANTES. Further biochemical and biophysical 
experiments are still needed to determine if a precise sequence dictates the binding of HS/heparin 
to RANTES and the subsequent activation of its corresponding chemokine receptors. 
To validate the IC50 values from the competitive ELISA assay, we calculated the valence-adjusted 
IC50 values for heparin and glycopolymers 1, 2, and 4 (Table 3). Since heparin contains a 
different number of sugar units per chain compared to the glycopolymers, this calculation allowed 
us to calibrate the IC50 values so that it would represent the activity of each bioactive epitope. For 
each of the glycopolymers, we accounted for the mass percentage of sugar contributing to the 
disaccharide-norbornyl linker unit; this value allowed us to calculate the valence-adjusted IC50 
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values. We then used the molecular mass of the differentially sulfated disaccharide units to 
determine the valence-adjusted IC50 values according to the molar concentration of disaccharide. 
As indicated in Table 3, the overall trends in RANTES inhibition for heparin and glycopolymers 
1, 2, and 4 remains the same after adjusting for valency; however, the potency of activity for 
glycopolymer 1 relative to heparin does improve by a modest factor. Fortuitously, by knowing the 
precise chemical structure of the molecules in hand, we were able to bypass the use of the 
carbazole assay[13] to calculate valence-adjusted concentration values. 
 
Table 3. Half maximal inhibitory concentration (IC50) for antagonists of RANTES. 
	  
 
Antagonist 
IC50 
(µg/mL)a 
IC50 
(nM)b  
IC50 
(µg/mL  
of disac)c 
IC50 
(µM  
of disac)d 
1 9.30 ± 1.1 335 ± 39 6.79 ± 0.80 11.7 ± 1.4 
2 31.1 ± 6.2 852 ± 170 21.8 ± 4.4 40.3 ± 8.0 
4 58.0 ± 5.7 1760 ± 170 40.6 ± 4.0 81.3 ± 8.0 
Heparin 0.900 ± 0.030 45.0 ± 1.5 0.900 ± 0.030 1.50 ± 0.050 
 
a  Values were determined from Figure 9 using KaleidaGraph software. Data represent the 
mean ± standard error for quadruplicate assays. 
b Values were calculated from Figure 9 based on molar concentration of antagonist (see 
Table 1 for molecular weights of glycopolymers 1-4). 
c Values were corrected for ligand valence after taking into account the mass percentage of 
disaccharide contributing to each disaccharide-norbornyl linker unit. 
d Values were corrected for ligand valence based on molar concentration of disaccharide.  
 
 
Anticoagulant Activity of the Glycopolymers 
After evaluating the ability of heparin and glycopolymers 1 – 4 to antagonize RANTES, we then 
evaluated their anticoagulant activities (in collaboration with Dr. Young In Oh). The binding of 
heparin polysaccharides to antithrombin III (ATIII) induces a conformational change that enables 
ATIII to inhibit the serine protease Factor Xa (FXa) in the coagulation cascade.[14] Specifically, 
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heparin binds to ATIII through a high-affinity glucosaminyl 3-O sulfated pentasaccharide that is 
found in one third of all heparin chains.[15] A methylated derivative of this pentasaccharide is now 
widely distributed as the drug Arixtra (GlaxoSmithKline), and the addition of an additional 
glucosaminyl 3-O-sulfate group has been shown to confer greater specificity for ATIII activation 
(Figure 10). Given that our glycopolymers lack the glucosaminyl 3-O sulfate modification, we 
hypothesized they would not be able to potentiate ATIII in an anticoagulant assay as heparin 
polysaccharides do. 
 
 
 
Figure 10. Chemical structures of pentasaccharide-based anticoagulant drugs Arixtra and Org31550. 
 
To measure anticoagulant activity, we incubated heparin or glycopolymer (10-5 – 500 µg/mL) in a 
purified system with ATIII and an excess of FXa. A conformational change in the structure of 
ATIII increases the protein’s inhibitory activity for FXa and can be evaluated in vitro using a 
chromogenic substrate specific for the proteolytic activity of FXa. By measuring the absorbance 
(405 nm) to determine the levels of residual chromogenic substrate, we could evaluate the ability 
of heparin or glycopolymers 1 – 4 to potentiate the inhibitory activity of ATIII. Importantly, none 
of the glycopolymers possessed any anti-FXa activity, while heparin was expectedly shown to be 
active in the same assay (Figure 11a). We also evaluated the ability of ATIII to inhibit Factor IIa 
(FIIa or Thrombin), which is activated downstream of FXa in the coagulation cascade as part of 
the common pathway. Unlike FXa, which utilizes a specific pentasaccharide sequence for ATIII 
activation, FIIa necessitates longer, highly sulfated template in order to form an inhibitory ternary 
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complex with ATIII.[16] In agreement with this molecular mechanism, we found that only heparin 
had significant anti-FIIa activity, while none of the glycopolymers were active (Figure 11b).  
 
     a                      b 
 
Figure 11. Glycopolymers 1 – 4 do not potentiate inhibition of thrombin in a purified system with antithrombin 
III. Human antithrombin III (1 IU/mL) was incubated with an excess of (a) Factor Xa or (b) Factor IIa (Thrombin) (24 
IU/mL) in the presence of either heparin or glycopolymer (10-5 – 500 µg/mL). Heparin is known to bind to and induce a 
conformational change in the structure of antithrombin III, thereby increasing its inhibitory activity for Factor Xa or 
Factor IIa (as observed in this assay). A chromogenic substrate (1.25 umol/mL) specific for the proteolytic activity of 
Factor Xa or Factor IIa was added to measure residual levels of coagulation factor. The absorbance was measured at 
405 nm and is inversely proportional to the ability of heparin or glycopolymer to potentiate the inhibitory activity of 
antithrombin III. Data represent the mean ± standard error for quadruplicate assays.     
 
Finally, we measured the ex vivo clotting times of the glycopolymers in comparison to heparin 
using human plasma samples. As the presence of other proteins in complex serum can potentially 
interfere with anticoagulant activity, these assays represent a more stringent test of anticoagulant 
efficacy. We measured the activated partial thromboplastin time (APTT) and prothrombin time 
(PT) of each compound to determine if the intrinsic and extrinsic pathways of the coagulation 
cascade are inhibited, respectively. While heparin (150 µg/mL) increased both the APTT and PT 
for blood clotting, glycopolymer 1 at the same concentration showed no appreciable change in 
APTT or PT (Table 4). Interestingly, the addition of glucosaminyl 3-O sulfation to glycopolymer 
1 drastically increased its APTT and PT values (data not shown; see Dr. Young In Oh’s thesis for 
experimental details), thus reinforcing the importance of this specific sulfate modification in the 
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context of glycosaminoglycan anticoagulant activity. Altogether, our results demonstrate that 
controlling the positioning of sulfate groups within the glycopolymer enables one to dissect the 
anti-inflammatory function of HS/heparin glycosaminoglycans from its anti-coagulant function. 
Furthermore, modifications to the sulfation motif can be distinctly exploited to adjust the affinity 
of the glycopolymers for specific HS/heparin-binding proteins. These efforts may facilitate the 
development of novel glycosaminoglycan-based therapeutic agents with fewer off-target side 
effects. 
 
Table 4. Ex vivo clotting times for heparin and glycopolymer 1. 
	  
Compound APTTa 
(s) 
PTa 
(s)	  
None 31.2 13.3 
Heparin >180 12.7 
1 46.1 84.2 
 
a  For 150 mg/mL of compound in citrated human plasma, n=3. 
 
 
Glycopolymer Activity in Cellular Assays 
The chemotactic activity of RANTES, which is essential to the clinical pathogenesis of allergic 
inflammatory responses such as asthma, is mediated in part by the chemokine receptor CCR3.[17] 
To test whether glycopolymer 1 can interfere with RANTES-induced chemotaxis via CCR3, we 
probed the migration of murine L1.2 pre-B cells that were stably transfected with CCR3 receptor 
(gift from Prof. Osamu Yoshi, Kinki University Faculty of Medicine, Japan).[18] Stable expression 
of CCR3 (and all other chemokine receptors mentioned in this study) was routinely confirmed by 
flow cytometry analysis. Using a modified Boyden chamber, we observed that the directional 
migration of L1.2-CCR3 cells (but not wild-type L1.2 cells lacking the expression of chemokine 
receptors) was dependent on RANTES concentration (0.5 – 1024 nM). In establishing the optimal 
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conditions for the migration assay, we systematically varied the incubation period (0.5 – 8 h), 
filter pore size (5 or 8 µm), and cell concentration (105 – 107 cells per pore). We discovered that a 
robust maximal response was elicited at 10 nM of RANTES (Figure 12a) upon placing 106 cells 
on a 5 µm filter pore and incubating the setup for four hours. While other conditions also elicited 
dose-dependent migration curves, the aforementioned parameters yielded the most consistent 
results in our hands. 
 
      a                      b 
 
Figure 12. RANTES-induced migration of CCR3- and CCR5-expressing cells. Chemotactic response to RANTES is 
maximal at (a) 10 nM for CCR3-stably transfected L1.2 cells and (b) 1 nM for CCR5-stably transfected L1.2 cells. In 
both experiments, wild-type L1.2 cells did not migrate in response to RANTES as expected. Chemotaxis was measured 
using a 96-well Boyden chamber, and the relative number of migrated cells was determined using a fluorescent nucleic 
acid dye. Data represent the mean ± standard error for two independent experiments conducted in quadruplicate.     
 
Using the same experimental conditions, we found that preincubation of RANTES (10 nM) with 
glycopolymer 1 or heparin (0.020 – 4.0 µg/mL) diminished the chemotactic activity of RANTES 
in a dose-dependent manner (Figure 13a). Further corroborating these observations, lower levels 
of RANTES were also detected on the surface of L1.2-CCR3 cells after the chemokine (100 nM) 
was pretreated with glycopolymer 1 or heparin, as determined by flow cytometry analysis (Figure 
14). Both glycopolymer 1 and heparin failed to block the migration of L1.2 cells transfected with 
CCR5 (see Figure 12b for migration curve, exhibiting a maximal response at 1 nM of RANTES), 
an alternative receptor for RANTES activity (Figure 13b). Consistent with these findings, the 
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reported binding sites for HS and RANTES exhibit considerable overlap on CCR3, whereas the 
two binding sites share no overlap on CCR5.[11] Altogether, our results show that glycopolymer 1 
effectively antagonizes the CCR3-dependent chemotactic activity of RANTES in various cellular 
assays, with comparable potency as heparin polysaccharides of the same length. Furthermore, we 
demonstrate the ability of these glycomimetics to selectively target specific chemokine-receptor 
interactions in the context of RANTES activation of the chemokine receptors CCR3 and CCR5.  
 
     a                     b 
 
 
Figure 13. RANTES-induced migration of (a) CCR3 and (b) CCR5-expressing L1.2 cells. RANTES (1 nM or 10 nM) 
was added to the bottom half of a 96-well modified Boyden chamber and preincubated with various concentrations of 
heparin or glycopolymer 1 prior to chemotaxis induction. The relative number of migrated cells was measured using a 
fluorescent nucleic acid dye. Heparin and glycopolymer 1 antagonizes the RANTES-induced migration of L1.2-CCR3 
cells, but did not affect the migration of L1.2-CCR5 cells except at the highest concentration of glycopolymer 1 (4 
µg/mL; *, P < 0.01; means were compared to RANTES treatment alone using a Student’s t test). Experiments were 
conducted in quadruplicate, and the standard error is depicted. 
 
 
 
 
In conclusion, we have developed a new class of HS mimetics that are synthetically accessible 
and highly tunable in structure and sulfation sequence. By controlling the sulfation sequence and 
exploiting the principles of multivalency to enhance glycan recognition, the binding affinity of 
HS disaccharides for protein binding partners can be amplified to target chemokines and their 
receptor interactions. We demonstrate that a trisulfated HS glycopolymer binds to RANTES with 
nanomolar affinity and inhibits the CCR3-dependent cellular response to this therapeutically 
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important chemokine, without affecting key components of the blood coagulation cascade. We 
envision that variations of these glycomimetics can be synthetically tailored in future studies to 
antagonize a wide range of HS/heparin-binding proteins with clinical relevance to atherosclerosis, 
cancer, and autoimmune disorders.  
 
 
 
Figure 14. RANTES binding to the surface of CCR3-expressing L1.2 cells. RANTES (100 nM) was preincubated with 
varying concentrations of heparin or glycopolymer 1 (0.02 – 2 µg/mL). Heparin or 1 inhibits the binding of RANTES 
to L1.2-CCR3 cells, as determined by flow cytometry (*, P < 0.05; means were compared to RANTES treatment alone 
using a Student’s t test). Data represent the mean ± standard error for three independent experiments, each conducted in 
quadruplicate. 
 
 
Experimental Methods  
Direct and Competitive Enzyme-Linked Immunosorbent Assay (ELISA) for RANTES. A 96-
well heparin-binding plate (BD Biosciences) was coated with 25 µg/mL of heparin (Neoparin) for 
12 h at rt. Wells were rinsed with phosphate-buffered saline (PBS) and blocked with 10% fetal 
bovine serum (FBS) in PBS for 1 h at 37 °C. For the direct ELISA, various concentrations of 
RANTES (0.50 – 1024 nM; R&D Systems) were serially diluted in 1% BSA in PBS and 
incubated in each well for 1.5 h at 37 °C. For the competitive ELISA, RANTES (at 12.2 nM, the 
pre-determined EC50; Figure 12) was preincubated (3 h, 37 °C) with various concentrations of 
heparin (0.010 – 40 µg/mL) or glycopolymers 1 – 4 (0.10 – 180 µg/mL), and the co-mixture was 
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added to the 96-well plate for 1.5 h at 37 °C. Wells were washed three times with PBST (PBS + 
0.1% Tween-20), incubated with a mouse anti-RANTES antibody (R&D Systems) for 1 h at 37 
°C, washed three times with PBST, and incubated with a horseradish peroxidase (HRP)-
conjugated anti-mouse IgG antibody (GE Healthcare Life Sciences) for 1 h at 37 °C. After three 
washes with PBST, RANTES binding was detected using a 3,3',5,5'-tetramethylbenzidine (TMB) 
substrate kit (Thermo Scientific) according to the manufacturer’s instructions. Absorbance was 
measured at 450 nm using a Victor 3 plate reader (PerkinElmer). The half-maximal effective 
concentration (EC50) and half maximal inhibitory concentration (IC50) were calculated using 
KaleidaGraph software (Synergy). IC50 values reported in the paper are for both the mass and 
molar concentrations of antagonist.  IC50 values were also corrected for ligand valence (Table 3) 
by calculating the mass percentage of the disaccharide epitope contributing to each disaccharide-
norbornyl linker unit, and then dividing by the molecular weight of the disaccharide epitope. 
 
Cell Culture. L1.2 cells (mouse pre-B lymphocytes) stably transfected with CCR3, CCR5, or 
vector only, were kindly provided by Dr. Osamu Yoshie (Kinki University, School of Medicine, 
Japan). Cells were maintained in RPMI 1640 (Invitrogen) supplemented with 10% FBS, 100 
µg/mL penicillin/streptomycin (Invitrogen), and 50 μM 2-mercaptoethanol (Sigma Aldrich). 
Cells were routinely analyzed by flow cytometry (FACSCalibur, Beckman Dickenson) to verify 
that cultures expressed adequate levels of chemokine receptor (>90%) for migration and cell 
binding assays. 
Cell Migration Assay. Experiments were performed using ChemoTx chambers (Neuroprobe). 
L1.2 cells (wild-type or stably-transfected with CCR3 or CCR5) were harvested and washed 
twice in flow cytometry buffer (Hank’s Balanced Salt Solution (HBSS) with 2.5 mg/mL bovine 
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serum albumin (BSA) and 10 mM HEPES). Human RANTES (R&D Systems) was serially 
diluted in flow cytometry buffer (0.5 – 1024 nM), and 30 µL of each dilution was added to the 
bottom wells of the ChemoTx chamber. Alternatively, in competitive migration assays, 1 or 10 
nM of RANTES was preincubated with various concentrations of heparin or glycopolymer 1 
(0.020 – 4.0 µg/mL) for 30 min at rt, and the same volume of each solution was added to the 
bottom wells. The sample plate was fitted with a 5-µm pore filter, and 106 cells (50 µL) were 
placed on top of each well. Cells were allowed to migrate through the filter for 4 h at 37 °C and 
5% CO2. Subsequently, non-migrating cells were removed from the top of the filter by manual 
scraping; cells adhering to the filter were dislodged using 20 µL of 2.5 mM EDTA for 30 min at 
rt. Migrated cells were transferred (500 x g, 5 min) to a 96-well black-walled clear-bottomed 
plate (Corning) using a funnel plate (Neuroprobe). Cells were lysed at -80 °C and stained with 
CyQUANT dye (Invitrogen) as described in the product literature. Fluorescence was measured at 
535 nm using a Victor 3 plate reader (PerkinElmer).   
 
Chemokine Cell Binding Assay. 3 x 106 L1.2 cells (wild-type or stably-transfected with CCR3) 
were washed twice with flow cytometry buffer and incubated with RANTES (100 nM in flow 
cytometry buffer) for 45 min at rt. Alternatively, cells were incubated with RANTES (100 nM in 
flow cytometry buffer) previously treated with various concentrations of heparin or glycopolymer 
1 (0.02 – 2 µg/mL) for 30 min at rt. Cells were spun twice (500 x g, 5 min) through 100% FBS 
(1.0 mL) to remove excess reagent and stained with phycoerythrin (PE)-conjugated anti-
RANTES (1 test) in FACS buffer (100 µL) for 1 h at 4 °C. Cells were again spun twice through 
100% FBS (1.0 mL) and resuspended in flow cytometry buffer (500 µL) for flow cytometry 
analysis. Immediately before analysis, 7-amino-actinomycin-D (7-AAD, 5 µL, eBioscience) was 
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added to evaluate cell viability. Cells were analyzed for PE intensity on a FACSCalibur flow 
cytometer (Beckman Dickenson, Caltech Flow Cytometry Facility) with 10,000 cell events per 
sample. Data analysis was performed using FlowJo (Tree Star Inc.). 
 
Chromogenic Assay for the Measurement of Antithrombin Activity. Factor Xa (FXa) Activity: 
The BIOPHEN Heparin Anti-FXa (2 stages) USP/EP kit (Aniara) was used to evaluate FXa 
activity. This chromogenic anti-FXa method for measuring homogeneous heparin in purified 
systems is in compliance with Pharmacopoeias (USP, EP) and FDA guidelines. All reagents were 
prepared according to manufacturer’s instructions and incubated at 37 °C for 15 min. Varying 
concentrations of heparin (Neoparin) or glycopolymers 1 – 4 (40 uL) and antithrombin (40 uL) 
were added to a microcentrifuge tube, mixed, and incubated at 37 °C for 2 min. FXa (40 uL) was 
added to the solution, incubated at 37 °C for exactly 2 min, and then the FXa chromogenic 
substrate (40 µL) was added. After 2 min, the reaction was quenched with citric acid (20 g/L, 240 
µL), and the absorbance was measured at 405 nm. The sample blank was obtained by mixing the 
reagents in reverse order, and the resulting value was deducted from the absorbance values 
measured in the assay.    
Factor IIa (FIIa) Activity: The BIOPHEN Heparin Anti-FIIa (2 stages) USP/EP kit (Aniara) was 
used to determine FIIa activity. This chromogenic anti-FIIa method was conducted according to 
the same procedure used for FXa. 
 
Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) Analysis. Flash 
frozen, platelet-poor human plasma with 3.2% citrate was purchased from Valley Biomedical 
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(Winchester, VA) for the coagulation assay. Samples were thawed at room temperature for 30 
min and used immediately for APTT and PT assays.   
For APTT analysis, samples were prepared by mixing 300 µL of heparin or glycopolymer in 
0.9% saline with 2.7 mL citrated human plasma. The tube was inverted three times to mix the 
sample thoroughly. Dade® Actin® activated cephaloplastin reagent was used as a plasma 
activator. To 100 µL of the plasma/anticoagulant sample, 100 µL of prewarmed APTT reagent 
(0.2% ellagic acid) was added. After incubation for 4 min, clotting was initiated by adding 100 
µL of 25 mM CaCl2 at 37 ºC and the time required for clot formation was measured. Clotting time 
in the absence of an anticoagulant was determined using 300 µL of saline solution. Each clotting 
assay was performed in triplicate. 
For PT analysis, samples were prepared by mixing 300 µL of heparin or glycopolymer in 0.9% 
saline with 2.7 mL citrated human plasma. The tube was inverted three times to mix the sample 
thoroughly. Dade® Innovin® reagent was reconstituted according to the manufacturer’s 
directions and warmed to 37 °C. 100 µL of the plasma/anticoagulant sample was incubated for 3 
min at 37 °C, followed by the addition of 200 µL of prewarmed thromboplastin reagent. The time 
required for clot formation was measured. Clotting time in the absence of an anticoagulant was 
determined using 300 µL of saline solution. Each clotting assay was performed in triplicate.   
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C h a p t e r  4  
DISCOVERY OF A SPECIFIC MODULATOR OF SDF-1 ACTIVITY 
Chemokine Binding to Synthetic Glycopolymers 
Our previous experiments showed that trisulfated glycopolymer 1 has the highest affinity (IC50 = 
9.30 ± 1.1 µg/mL (335 ± 39 nM)) for the pro-inflammatory chemokine RANTES compared to the 
other sulfated glycopolymers in our synthetic library. While heparin polysaccharide of the same 
length (IC50 = 0.900 ± 0.03 µg/mL (45.0 ± 1.5 nM) bound to RANTES more efficiently than 
glycopolymer 1, both antagonists exhibited similar potencies in cell migration and binding assays. 
As cell migration and chemotactic gradients play an essential role during angiogenesis, here we 
sought to compare the relative binding affinities of glycopolymer 1 and heparin for a series of 
chemokines strongly implicated in angiogenesis.[1] Specifically, we chose to examine growth 
related oncogene-α (Gro-α; CXCL1), interleukin 8 (IL-8; CXCL8), and stromal cell-derived 
factor 1 (SDF-1; CXCL12), three members of the CXC subfamily. 
CXC chemokines are known for their ability to regulate angiogenesis,[2] the physiological process 
by which new blood vessels are derived from existing capillaries. All CXC chemokines have four 
highly conserved cysteine residues, and the first two cysteines are separated by a nonconserved 
residue.[3] A second structural domain in these chemokines dictates their angiogenic capacity: that 
is, a tripeptide sequence (Glu-Leu-Arg; also designed the ELR motif) at the N-terminus preceding 
the first cysteine residue in the CXC domain.[4] Typically, members that have the ELR motif 
(ELR+) are potent inducers	  of angiogenesis, while those lacking the motif (ELR-) are inhibitors.[5] 
Thus, the local expression of specific CXC chemokines can serve as an important regulator of 
angiogenesis; likewise, an imbalance in chemokine expression can have dire consequences, such 
as the promotion of tumor growth or the induction of chronic fibroproliferative disorders.[6] Two 
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of the chemokines that we chose to investigate, Gro-α and IL-8, are distinctly pro-angiogenic 
(ELR+) and can act as ligands for CXCR2,[7] a chemokine receptor upregulated in several cancers 
of high metasatic index (breast cancer,[8] head and neck cancer,[9] melanoma,[10] ovarian cancer,[11] 
pancreatic cancer[12]). We also chose to evaluate SDF-1, the only ELR- chemokine that is able to 
potentiate angiogenesis and other growth promoting activities. In fact, SDF-1 has been shown to 
play a major role in recruiting CXCR4-positive bone marrow and tumor cells to neo-angiogenic 
niches to support the revascularization of ischemic tissues[13] and tumor microenvironments.[14]  
 
Table 5. Half maximal inhibitory concentration (IC50) for antagonists of Gro-α, IL-8, and SDF-1. 
	  
 
Antagonist 
IC50 
(µg/mL)a 
IC50 
(nM)b  
IC50 
(µg/mL  
of disac)c 
IC50 
(µM  
of disac)d 
Gro-α  
1 77.4 2780 56.5 97.6 
Heparin 2.41 121 2.41 4.17 
IL-8 
1 5.66 203 4.13 7.13 
Heparin 22.8 1140 22.8 39.4 
SDF-1 
1 2.70 97.0 1.97 3.41 
2 16.4 449 11.5 21.3 
Heparin 44.3 2210 44.3 76.4 
 
a  Values were determined from Figure 15 using KaleidaGraph software. Data represent 
the mean ± standard error for quadruplicate assays. 
b Values were calculated from Figure 15 based on molar concentration of antagonist (see 
Table 1 for molecular weights of glycopolymers 1-4). 
c Values were corrected for ligand valence after taking into account the mass percentage of 
disaccharide contributing to each disaccharide-norbornyl linker unit. 
d Values were corrected for ligand valence based on molar concentration of disaccharide.  
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Figure 15. Comparison of the ability of glycopolymer 1 and heparin to compete for binding to (a) RANTES; (b) Gro-
α; (c) IL-8; (d) SDF-1. IC50 values corrected for ligand valence are reported in Table 5. 
 
First, we determined the EC50 values of Gro-α, IL-8, and SDF-1 binding to heparin-coated (25 
µg/mL) 96-well plates using a direct ELISA format (166 nM, 38 nM, and 315 nM, respectively). 
We then evaluated the ability of glycopolymer 1 or heparin to inhibit each of the chemokines at 
its EC50 value using the same competitive ELISA procedure developed for RANTES. While the 
IC50 values for heparin-mediated chemokine inhibition reflected the EC50 values from the direct 
ELISA, we were surprised to find that the IC50 values for glycopolymer-mediated chemokine 
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inhibition were drastically different from the EC50 values (Table 5 and Figure 15). For example, 
heparin inhibited Gro-α (EC50 = 166 nM) with expected nanomolar affinity (IC50 = 2.41 µg/mL or 
121 nM), while glycopolymer 1 was found to be 30-fold less effective (IC50 = 77.4 µg/mL or 
2780 nM). In contrast, heparin exhibited slightly reduced affinity for IL-8 (EC50 = 38 nM; IC50 = 
22.8 µg/mL or 1140 nM) in comparison to glycopolymer 1 (IC50 = 5.66 µg/mL or 203 nM). 
Despite these discrepancies, we were pleased to discover that glycopolymer 1 bound to SDF-1 
(EC50 = 315 nM; IC50 = 2.70 µg/mL or 97.0 nM) with tight nanomolar affinity, while heparin was 
notably less efficient (IC50 = 44.3 µg/mL or 2210 nM). This result suggests that structural features 
unique to glycopolymer 1 (unrelated to sulfation) endowed it with the ability to act as a more 
specific antagonist of SDF-1. 
 
 
Figure 16. Comparison of the ability of glycopolymers 1 – 4 and heparin to compete for binding to SDF-1. IC50 values 
corrected for ligand valence are reported in Table 1. 
 
We also investigated whether modifications to the sulfation motif would alter the glycopolymer’s 
ability to inhibit SDF-1. Similar to our observations with RANTES, we found that removal of the 2-
O sulfate group on IdoA (glycopolymer 4; IC50 = 16.4 µg/mL or 449 nM) had a more drastic effect 
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on SDF-1 binding affinity than removal of the N-sulfate group on GlcN (glycopolymer 2; IC50 
undeterminable) (Table 5 and Figure 16). As expected, the unsulfated control (glycopolymer 3) did 
not exhibit any appreciable binding to SDF-1. Interestingly, glycopolymer 2 was determined to be a 
more effective inhibitor of SDF-1 than heparin itself, despite possessing fewer sulfate groups per 
sugar unit. These findings suggest that the macromolecular architecture of the glycopolymer is 
inherently favorable for SDF-1 interactions and may even promote the formation of higher-order 
SDF-1 oligomers. However, further structural insights (such as molecular docking simulations) are 
still needed for one to be able to predict the biochemical behavior of the synthetic glycopolymers. 
The development of such efforts would greatly facilitate the design of highly specific antagonists 
for targeting chemokine activity. 
 
Glycopolymer Modulation of SDF-1 Activity  
Given the remarkable and unexpected affinity of glycopolymer 1 for SDF-1, we sought to examine 
how glycopolymer modulated SDF-1 activity in a cellular context. As previously mentioned, SDF-1 
signaling through its primary receptor CXCR4 has been strongly linked to cancer metastasis in the 
context of tumor-associated immune cells, neo-angiogenesis, invasion, and proliferation. At least 23 
types of cancers have been shown to upregulate CXCR4 within the tumor microenvironment and 
are highly sensitized to SDF-1 gradients originating from distant tissues (e.g. bone marrow, lung, 
liver).[15] Current efforts to block the metastatic dissemination of malignant cancers have primarily 
focused on the development of small molecule CXCR4 antagonists; unfortunately, such compounds 
have proven to be remarkably difficult to transfer into the clinic.[15] Thus, alternative strategies are 
still needed for targeting SDF-1 mediated metastatic homing of invasive cancer cells, such as direct 
inhibition of SDF-1 itself and/or alterations to its oligomerization state. 
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Both SDF-1 and cognate receptor CXCR4 are known to play vital roles in leukocyte trafficking,[16] 
hematopoiesis,[17] and development.[18] While gene knockouts of most chemokines and chemokine 
receptors exhibit no apparent phenotype due to the inherent redundancy of the chemokine system, 
SDF-1-/- and CXCR4-/- mice both display significant defects in B-cell lymphopoiesis, bone marrow 
myelopoiesis, vascularization of the gastrointestinal tract, cardiac ventral septum formation, and 
cerebellar development.[19] In addition to normal physiological functions, SDF-1 and CXCR4 also 
contribute to the pathogenesis of several types of cancer[20] by controlling the metastasis of CXCR4-
expressing tumor cells towards SDF-1-secreting organs. Given the multifunctional and diverse roles 
of SDF-1 and CXCR4, we sought to determine if glycopolymer 1 could effectively disrupt the 
migration of CXCR4-expressing cells towards a SDF-1 chemoattractant gradient.  
We chose to use the Jurkat T cell line, as it is known to express high levels of endogenous CXCR4 
and respond accordingly to SDF-1-mediated chemotaxis.[21] Using a modified Boyden chamber, we 
observed that maximal migration of Jurkat cells occurred at 5 nM of SDF-1 using assay conditions 
previously optimized for L1.2 cells (5 µm filter pore, 4 hour incubation at 37 °C, 106 cells per pore). 
We found that the percentage of cells migrating in response to SDF-1 gradients could be further 
improved by reducing the number of cells per pore to 105. Using these modified conditions, we 
found that precinbuation of SDF-1 (5 nM) with glycopolymer 1 (0.02 – 10 µg/mL) blocked the 
chemotactic activity of SDF-1 in a dose-dependent manner, while heparin administered at the same 
concentrations had no appreciable effect (Figure 17). The potent inhibition of SDF-1 mediated cell 
migration by glycopolymer 1 is consistent with the IC50 value that we measured in the competitive 
ELISA and implicates the potential use of synthetic glycomimetics as anti-metastasis agents in 
CXCR4-expressing tumor microenvironments. Furthermore, the distinct ability of glycopolymer 1 
to recognize of SDF-1 over other chemokines in the competitive ELISA suggests that glycopolymer 
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1 could serve as a specific inhibitor of SDF-1 at effective concentrations for which heparin/HS 
polysaccharides show no activity.  
 
 
 
Figure 17. SDF-1-induced migration of CXCR4-expressing Jurkat cells. SDF-1 (5 nM) was added to the bottom half 
of a 96-well modified Boyden chamber and preincubated with various concentrations of heparin or glycopolymer 1 
prior to chemotaxis. The relative number of migrated cells was measured using a fluorescent nucleic acid dye. 
Glycopolymer 1 antagonizes the SDF-1-induced migration of Jurkat cells (*, P < 0.01; means were compared to SDF-1 
treatment alone using a Student’s t test), while heparin at the same concentrations exhibited no effect. Experiments 
were conducted in quadruplicate, and the standard error is depicted. 
 
Under physiological conditions, SDF-1 exists in a monomer-dimer equilibrium that can be altered 
by chemokine concentration, pH, the presence of anions (phosphate, sulfate, citrate), and heparin. 
Acidic pH is known to promote the monomeric state by destabilizing the dimeric structure, while 
negatively charged species have been shown to shift the equilibrium towards dimer formation.[22] 
Furthermore, the monomeric form of SDF-1 is responsible for mobilization of intracellular calcium, 
inhibition of cAMP signaling, recruitment of β-arrestin, stimulation of actin polymerization, and 
cellular migration, and thus is highly linked to mechanisms of cancer metastasis dictated by SDF-1 
gradients.[23] Conversely, dimeric SDF-1 is able to induce G-protein-dependent calcium flux, inhibit 
adenylyl cyclase, and rapidly activate ERK1/2, mechanisms that are associated instead with cell 
survival.[23] Micromolar amounts of heparin are typically required to induce SDF-1 dimerization; 
thus, the heparin concentrations (0.02 – 10 µg/mL) used in the migration assay would not have been 
sufficient to block SDF-1-mediated chemotaxis by promoting dimer formation. However, we did 
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observe full inhibition of SDF-1 activity for 2 µg/mL of glycopolymer 1 in the same assay (Figure 
17). This observation led us to reason that relatively low concentrations of glycopolymer 1 might be 
sufficient to block SDF-1-mediated cell migration due to a shift in the monomer-dimer equilibrium 
towards the latter species. 
 
a                                                                       b                                                         
 
 
Figure 18. SDF-1-induced ERK1/2 phosphorylation of CXCR4-expressing Jurkat cells. ERK1/2 phosphorylation 
levels are measured by immunoblotting for phosphorylated and total ERK1/2, and the ratio of their relative intensities 
is plotted. (a) SDF-1 (0.5 ng/mL) induces a maximal response in ERK1/2 phosphorylation at 1 minute, which gradually 
decreases over 30 minutes. (b) Glycopolymer 1 potentiates the ERK1/2 phosphorylation after 5 min (*, P < 0.05; 
means were compared to SDF-1 treatment alone using a Student’s t test), while heparin at the same concentrations has 
no effect. Experiments were conducted in triplicate, and the standard error is depicted. 
 
To further explore this hypothesis, we examined the intracellular signaling pathways modulated by 
SDF-1 and CXCR4 in Jurkat cells. The dimer form of SDF-1 has been shown to preferentially 
induce downstream activation of ERK1/2 to control cell proliferation and cell death.[24] To verify 
that SDF-1 can activate the ERK1/2 pathway in Jurkat cells, we measured phosphorylation levels of 
ERK1/2 after exposure to the chemokine. Immunoblotting with phospho-ERK1/2 antibody revealed 
that SDF-1 treatment (0.5 ng/mL) led to rapid activation of ERK1/2, with phosphorylation levels 
peaking at 1 min after SDF-1 exposure (Figure 18a). ERK1/2 phosphorylation was sustained for at 
least 30 min and was completely abrogated upon pretreatment of the cells with CXCR4-specific 
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antagonist AMD3100 (100 ng/mL; Figure 18b). No significant changes were observed in total ERK 
expression during the same time period. Next we evaluated the ability of glycopolymer 1 or heparin 
to alter the phosphorylation status of ERK1/2 at 5 min after exposure to SDF-1. Notably, we found 
that glycopolymer 1 (200 µg/mL) potentiated the activation of ERK1/2 by 1.8-fold, while the same 
concentration of heparin had no effect (Figure 18b), thus further validating our hypothesis that the 
glycopolymer promotes the dimer form of SDF-1. However, detailed biophysical experiments are 
still warranted to demonstrate that natural glycosaminoglycans and synthetic glycomimetics induce 
differential changes in SDF-1 structure and CXCR4 signaling. 
The ability to differentially activate CXCR4 pathways by modulating the oligomerization status of 
its ligand would provide an exciting new strategy for therapeutic invention of many diseases. For 
example, the monomer form of SDF-1 is believed to be cardioprotective, as an obligate monomer of 
SDF-1 has recently been proposed to potentially treat ischemia-reperfusion injuries and myocardial 
infarctions.[25] In the context of cancer metastasis, however, an obligate dimer of SDF-1 has been 
shown to preferentially inhibit the metastasis of colonic carcinoma and pulmonary melanoma cells 
ex vivo, presumably due to the formation of nonmotogenic SDF-1 dimers. Our experiments here 
show that trisulfated glycopolymer 1 bound to SDF-1 with high affinity, and the resulting complex 
recapitulated the inhibitory activity of the SDF-1 dimer in two preliminary in vitro assays. In 
contrast, similar complexes formed by heparin and SDF-1 did not show any activity. If additional 
biophysical experiments are able to demonstrate that glycopolymer 1 does preferentially bias the 
SDF-1 equilibrium towards the dimer form, we propose that this synthetic mimetic could potentially 
be used as a treatment for several types of invasive cancers relying on SDF-1 gradients, including 
breast carcinoma,[26] liver carcinoma,[27] and highly malignant cases of glioblastoma multiforme.[28] 
We anticipate that this strategy will have several advantages over current efforts to block the 
CXCR4 receptor, since it would allow for direct disruption of local SDF-1 gradients at the tissue 
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harboring the tumor microenvironment and the preservation of SDF-1 dimer signaling necessary for 
cell proliferation and other homeostatic functions. Furthermore, the highly tunable nature of the 
glycopolymer structure will enable the eventual development of tissue-specific inhibitors of SDF-1 
in the context of specific metastatic cancers. 
 
Experimental Methods  
Direct and Competitive Enzyme-Linked Immunosorbent Assay (ELISA) for SDF-1. A 96-well 
heparin-binding plate (BD Biosciences) was coated with 25 µg/mL of heparin (Neoparin) for 12 h 
at rt. Wells were rinsed with phosphate-buffered saline (PBS) and blocked with 10% fetal bovine 
serum (FBS) in PBS for 1 h at 37 °C. For the direct ELISA, various concentrations of SDF-1 
(0.50 – 1024 nM; R&D Systems) were serially diluted in 1% BSA in PBS and incubated in each 
well for 1.5 h at 37 °C. For the competitive ELISA, SDF-13 (at 315 nM, the pre-determined EC50 
value) was preincubated (3 h, 37 °C) with various concentrations of heparin (0.010 – 40 µg/mL) 
or glycopolymers 1 – 4 (0.10 – 270 µg/mL), and the co-mixture was added to the 96-well plate 
for 1.5 h at 37 °C. Wells were washed three times with PBST (PBS + 0.1% Tween-20), incubated 
with a mouse anti-SDF-1 antibody (R&D Systems) for 1 h at 37 °C, washed three times with 
PBST, and incubated with a horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody 
(GE Healthcare Life Sciences) for 1 h at 37 °C. After three washes with PBST, SDF-1 binding 
was detected using a 3,3',5,5'-tetramethylbenzidine (TMB) substrate kit (Thermo Scientific) 
according to the manufacturer’s instructions. Absorbance was measured at 450 nm using a Victor 
3 plate reader (PerkinElmer). The half-maximal effective concentration (EC50) and half maximal 
inhibitory concentration (IC50) were calculated using KaleidaGraph software (Synergy). IC50 
values reported in the paper are for both the mass and molar concentrations of antagonist.  IC50 
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values were also corrected for ligand valence (Table 5) by calculating the mass percentage of the 
disaccharide epitope contributing to each disaccharide-norbornyl linker unit, and then dividing by 
the molecular weight of the disaccharide epitope. 
 
Cell Culture. CXCR4-expressing Jurkat T cells were maintained in RPMI 1640 (Invitrogen) 
supplemented with 10% FBS, 100 µg/mL of penicillin/streptomycin (Invitrogen), and 50 μM of 
2-mercaptoethanol (Sigma Aldrich). Cells were routinely analyzed by flow cytometry 
(FACSCalibur,	  Beckman Dickenson) to verify adequate expression of the chemokine receptor. 
 
Cell Migration Assay. Experiments were performed using ChemoTx chambers (Neuroprobe). 
CXCR4-expressing Jurkat cells were harvested and washed twice in flow cytometry buffer 
(Hank’s Balanced Salt Solution (HBSS) with 2.5 of mg/mL bovine serum albumin (BSA) and 10 
mM of HEPES). Human SDF-1 (R&D Systems) was serially diluted in flow cytometry buffer 
(0.5 – 1024 nM), and 30 µL of dilution was added to the bottom wells of the ChemoTx chamber. 
Alternatively, in competitive migration assays, 5 nM of SDF-1 was preincubated with various 
concentrations of heparin or glycopolymer 1 (0.020 – 10 µg/mL) for 30 min at rt, and the same 
volume of each solution was added to the bottom wells. The sample plate was fitted with a 5-µm 
pore filter, and 105 cells (50 µL) were placed on top of each well. Cells were allowed to migrate 
through the filter for 4 h at 37 °C and 5% CO2. Subsequently, non-migrating cells were removed 
from the top of the filter by manual scraping; cells adhering to the filter were dislodged using 20 
µL of 2.5 mM EDTA for 30 min at rt. Migrated cells were transferred (500 x g, 5 min) to a 96-
well black-walled clear-bottomed plate (Corning) using a funnel plate (Neuroprobe). Cells were 
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lysed at -80 °C and stained with CyQUANT dye (Invitrogen) as described in the product 
literature. Fluorescence was measured at 535 nm using a Victor 3 plate reader (PerkinElmer).   
 
ERK1/2 Phosphorylation Assay. A total of 107 cells in 1 ml of RPMI 1640 media were 
equilibrated for 5 min at 37 °C and then stimulated with SDF-1 (0.5 ng/mL) alone or SDF-1 
preincubated with various concentrations of heparin or glycopolymer 1 (1 – 100 ng/mL). 
Reactions were terminated by the addition of ice-cold PBS (1 mL). Cells were pelleted in a 
microcentrifuge for 45 s, followed by aspiration of the supernatant and the addition of 0.5 mL of 
ice-cold cell lysis buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% NP-
40, 0.5%SDS, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, and 1 mM NaF) containing protease 
and phosphatase inhibitor cocktail (Roche). Lysates were clarified by centrifugation at 10,000 x g 
for 10 min, and the total protein concentrations were determined by BCA Protein Assay (Pierce). 
Equal amounts (30 µg) of total protein were separated by SDS-PAGE on 4-12% Bis-Tris gels 
(Invitrogen) and transferred to PVDF membranes. After blocking in 5% BSA for 1 h at rt, the 
membranes were incubated overnight at 4 °C with primary antibodies to ERK42/44 and phospho-
ERK42/p44 (Cell Signaling Technology). After excessive washing with TBS containing 0.1% 
Tween 20, the membranes were probed with IR-labeled secondary Antibodies (Rockland 
Immunochemicals) for 1 h at rt. Membranes were then washed with TBS containing 0.1% Tween 
and scanned under both the 700 and 800 channels using the Odyssey Infrared Imaging System 
(LI-COR Bioscience). 
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